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Cerebral palsy (CP) is a permanent disorder caused by a non-progressive brain injury or 
malformation that has occurred early in the development of the child’s brain. The disorder is 
characterized by dysfunction of movement and posture, with frequent but variable 
occurrences of other dysfunctions in cognition, perception, sensation, communication, as well 
as of epilepsy, and pain. The movement dysfunctions are often what is most apparent for an 
outside observer and interventions have traditionally focused primarily on movement. 
Spasticity, a type of abnormal contraction of muscles, is common in CP and an aspect of 
movement that is often targeted for treatment. As CP is a life-long disorder it is important to 
understand the long-term effects of treatments, especially if they are performed early in life. It 
is also important to understand how the disorder and the consequences of the disorder evolve 
‘long-term’ as the individual grows up. Our knowledge of CP after childhood has been 
limited. Concerns have been raised on the topics of integration into society for adults with 
CP, and on some emerging health issues; especially a high prevalence of chronic pain. 
Understanding these issues and finding ways to manage them is a priority. 
This thesis focuses on the health and social situation of individuals with CP right after 
childhood, and on specific treatments for spasticity and pain. This was done using a few 
separate methods. Health and social situation were investigated cross-sectionally in 20-22-
year-old young adults with CP. The long-term effects of the spasticity-reducing neurosurgical 
procedure selective dorsal rhizotomy (SDR) were investigated using a consecutive case 
series. And botulinum toxin-A (BoNT-A) was tested as a treatment for chronic muscle-
related pain in adults with CP by means of a randomized, placebo-controlled, double-blinded 
clinical trial.  
It was found that most young adults with CP still lived in their parental home; more so than in 
the general population. A majority of those without an intellectual disability had an 
occupation, but the risk of having no occupation at all was increased. Communication 
function classification level (CFCS), and intellectual disability were major determinants of 
the social outcomes, while gross motor function classification level (GMFCS) was not. The 
overall health-related quality of life (HRQoL) of young adults with CP was comparable to 
population norms. There were, however, significant sub-group differences across different 
levels of gross motor function. Pain and fatigue were prevalent across all levels of 
functioning.  
The SDR procedure was effective in the long term in reducing spasticity, but this did not 
prevent contracture development, nor did it seem to improve functioning. Finally, BoNT-A 
was not superior to placebo in reducing pain in adults with CP at six weeks after treatment. 
Pain intensity did, however, trend downwards in the BoNT-A group at the last follow-up, 
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1.1 CEREBRAL PALSY 
1.1.1 Definition, etiology and prevalence 
Cerebral palsy (CP) is defined as a group of permanent disorders of the development of 
movement and posture, that are attributed to non-progressive disturbances that occurred in the 
developing fetal or infant brain (Rosenbaum et al., 2007). These non-progressive disturbances 
are most often transient destructive processes that injure the brain, most commonly identified 
as hypoxia-ischemia, infections or focal infarcts (Bax et al., 2006). Congenital causes (i. e. 
not injuries) such as malformations or purely molecular genetic disorders are less common 
(Bax et al., 2006; MacLennan et al., 2015). The etiology of the destructive process can be 
singular (such as a single cerebrovascular event) but is probably often a combination of 
precipitating events (such as prematurity, growth restriction and inflammation) (Leviton et 
al., 2013; McIntyre et al., 2013). Acute intrapartum hypoxia has historically been assumed to 
be the main cause of CP but has been estimated to account for less than 10% of cases 
(Ellenberg & Nelson, 2013; Nelson & Ellenberg, 1986). 
An important prerequisite for the cerebral palsy diagnosis is that the non-progressive 
disturbance to the brain “occurred in the developing fetal or infant brain” (Rosenbaum et al., 
2007), emphasizing that the disturbance resulting in CP happened before or during the 
development of the affected function (such as hand manipulation or walking) (Rosenbaum et 
al., 2007). There is no explicit age limit, but disturbances occurring after two years of age are 
generally not considered CP (Rosenbaum et al., 2007), and most national registries reporting 
on prevalence figures (see below) exclude post-neonatal cases (Galea et al., 2019; Hollung et 
al., 2018; Sellier et al., 2016). 
The most recent reported birth prevalence of CP in western Europe is 1.77 per 1000 live 
births (or 0.17%) (Sellier et al., 2016), with a 99% confidence interval (CI) between 1.57-
1.99. Similar figures have recently been reported from Australia (Galea et al., 2019). Both 
reports note that the prevalence of CP is decreasing when comparing more recent birth 
cohorts with birth cohorts from the 1980-1990’s, where the prevalence was at or above 0.20% 
(Galea et al., 2019; Sellier et al., 2016). This decrease is thought to be due to improvements in 
prenatal and postnatal/neonatal care (Galea et al., 2019; Sellier et al., 2016). 
1.1.2 Clinical characteristics and classifications 
As the definition states, CP comprises a group of clinical disorders. Further delineation is 
necessary. The movement aspects of the disorder take precedence in the ensuing 
categorization. Other aspects of function are, however, gaining in importance, as discussed 
further on. The guidelines issued in 2000 by the Surveillance of Cerebral Palsy in Europe 
collaboration (SCPE) remain the gold standard in classifying the clinical sub-types of CP 
(Cans et al., 2000) (Figure 1). The clinical sub-types of CP are spastic bilateral, spastic 
unilateral, dyskinetic (with further sub-classification into dystonic and choreoathetoid), 
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ataxic, and unclassifiable.  Further distinctions are made using classification systems of 
functional abilities. These classification systems play a major role in this thesis. The Gross 
Motor Function Classification System (GMFCS) (Figure 2) (Palisano et al., 1997), revised in 
2008 (Palisano et al., 2008) was the first classification system. It has since gained universal 
use clinically and in research as well as served as a model for subsequent classification 
systems. It classifies gross motor functioning into five levels ranging from high motor 
functioning in level I to low motor functioning in level V (Figure 2). The GMFCS has been 
shown to be valid, reliable, stable over time and predictive of long term motor functioning 
(Hanna et al., 2009; Palisano et al., 2006; Palisano et al., 2008; Palisano et al., 1997). 
Although developed for children, the updated version (GMFCS-ER) (Palisano et al., 2008) 
has been shown to be valid also for adults (Jahnsen et al., 2006). The GMFCS is associated 
with the presence and severity of accompanying impairments such as intellectual disability 
(ID), epilepsy, impairments of vision and hearing, and more (Delacy et al., 2016; 
Himmelmann et al., 2006). Thus, the clinical sub-type and the GMFCS, both descriptors of 
movement, have been established as the basis for classifying CP in an individual. The Manual 
Ability Classification System (MACS) (Eliasson et al., 2006) is constructed analogous to the 
GMFCS and classifies hand performance/manual ability on a five level scale. The MACS has 
equally gained widespread use in the clinical setting and in research (Rosenbaum et al., 
2014). 
Given that the basis for the disorder is any early non-progressive brain injury or malformation 
(be it large or small, well-defined or diffuse) that gives rise to motor signs and symptoms, it is 
only logical to assume that other central nervous system functions, besides movement, often 
are affected. This is indeed the case; intellectual disability is present in about half of 
individuals with CP, epilepsy in a third, with impairments of vision, hearing, communication, 
Figure 1. Hierarchical decision tree for classifying cerebral palsy sub-types. Adapted from Surveillance of 
Cerebral Palsy in Europe – Cans et al. (2000). 
Persisting increased muscle tone in one or more limbs
Yes No
Both sides of the body involved
Yes No




Generalized hypotonia with signs of ataxia
Yes No









Dystonic CP Choreoathetotic CP
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behavior, amongst other co-morbidities, also being common (Novak et al., 2012). This has 
also been recognized in the latest definition of CP (Rosenbaum et al., 2007). The co-
morbidities are, as mentioned above, not uniformly distributed in individuals with CP but 
more common when there is more motor activity limitation and less common (but not 
necessarily absent) when there is less motor activity limitation (Delacy et al., 2016; 
Himmelmann et al., 2006). 
 
Figure 2. Illustrations of the five levels of the Gross Motor Function Classification System. Courtesy of Prof. K. 
Graham, The Royal Children's Hospital, Melbourne. Reprinted with permission. 
 
4 
Functional levels of communication have been formalized in the Communication Function 
Classification System (CFCS) (M. J. Hidecker et al., 2011). It similarly has five levels, and 
has been found to complement the GMFCS and the MACS in that the combination of the 
three systems gives a more comprehensive picture of functioning in children with CP (M. J. 
C. Hidecker et al., 2012). The impact and usefulness of these systems have resulted in 
additional classification systems being published, for example, the Eating And Drinking 
Classification System (EADCS) (Sellers et al., 2014) and the Visual Function Classification 
System (VFCS) (Baranello et al., 2020). The classification systems share a number of 
common features. Noteworthy are that the systems focus on what an individual does as 
opposed to their difficulties (i. e. achievement rather than deficit), and that the systems 
classify performance (children/adults’ usual activity) as opposed to capacity (what an 
individual can do at their best) (Rosenbaum et al., 2014). The systems do not weigh how 
‘normally’ an individual performs an activity (Rosenbaum et al., 2014).  
1.2 HEALTH AND WELL-BEING IN CEREBRAL PALSY 
1.2.1 The concept of health 
In 1946, the World Health Organization (WHO) agreed upon a definition of health that is still 
in use, stating that “health is a state of complete physical, mental and social well-being and 
not merely the absence of disease or infirmity” (World Health Organization, 1946). Apparent 
to most but still an important reminder to some is that having a disability does not exclude 
enjoying good health. That social life is an integral part of overall health is another reminder. 
1.2.2  Aspects of disability 
Disability can be conceptualized as 1) a medical problem; a feature of the person directly 
caused by disease or trauma, where the solutions are medical treatments or other 
interventions aimed at ‘normalizing’ or correcting the feature, or 2) a socially created 
problem; that disability is not about the individual herself but instead caused by an 
unaccommodating environment, where solutions are interventions aimed at correcting the 
environment (World Health Organization, 2002). In reality, disability is a complex interplay 
between both concepts. Drawing upon these models and their complex interactions, the WHO 
has developed the International Classification of Functioning, Disability and Health (ICF) 
(World Health Organization, 2001) as a universal classification for health and disability and a 
framework for understanding this interplay. Whereas the International Classification of 
Diseases (ICD) (World Health Organization, 2004) helps in structuring diagnoses correctly, 
the ICF helps in structuring functioning correctly. A notable feature of the ICF framework is 
the division of human functioning into three levels: the level of body or body part, of the 
whole person, and the whole person in a social context (World Health Organization, 2002). 
Correspondingly, disability involves dysfunction at one or more of these three levels, namely 
as ‘impairment’ (body or body part), ‘activity limitation’ (whole person), or as ‘participation 
restriction’ (whole person in a social context). The framework is therefore two-sided: body 
structure and function, and activity and participation denote the “positive aspects”: the health 
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or functioning of the individual. Impairment, activity limitation and participation restriction 
denote the “negative aspects”: the disability(World Health Organization, 2013). Disability 
and functioning are regarded as outcomes of the interactions between these health conditions 
and the contextual factors; namely environmental factors (such as societal attitudes, legal and 
social structures, the physical structuring of public milieus) and personal factors (such as age, 
gender, social background, and coping style) (World Health Organization, 2002). 
The concepts of the ICF have been part of a general shift in the way CP is approached 
clinically and scientifically (Rosenbaum & Gorter, 2012). It has helped to shift focus from 
body structure and function-oriented interventions to interventions instead directly aimed at 
improving activity and participation (Novak et al., 2013; Rosenbaum & Gorter, 2012). In 
other words – a shift from ‘correcting’ or ‘normalizing’ impairments to that of promoting 
activity, and achieving societal participation and self-set goals (Rosenbaum & Gorter, 2012). 
1.2.3 Quality of life 
Measuring well-being is the mission of quality of life (QoL) instruments. The WHO defines 
quality of life as “an individual’s perception of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns” (World Health Organization, 1997). This has not been the only 
attempt to delineate and define the concept. Considerable uncertainty remains in separating 
the concepts of QoL, health-related quality of life (HRQoL), and health status (Karimi & 
Brazier, 2016). In an attempt to distinguish HRQoL from QoL the following definition has 
been presented: “Quality of life is an all-inclusive concept incorporating all factors that 
impact upon an individual’s life. Health-related quality of life includes only those factors that 
are part of an individual’s health” (Torrance, 1987), meaning that, for example, economic or 
political considerations should be omitted from the HRQoL concept. It has been argued that 
common HRQoL instruments in fact measure health, as per the WHO definition of health 
(World Health Organization, 1946), and should therefore be referred to as measures of ‘health 
status’ or ‘self-perceived health’ (Karimi & Brazier, 2016). In this thesis, the terms ‘HRQoL’, 
‘health status’ and ‘self-perceived health’ will be used interchangeably. 
1.2.4 Young adulthood 
The period of life characterized by transition from childhood to adulthood is of interest when 
looking at a life-long childhood-onset disability such as CP. This is because information on 
health at this time can be used to inform ‘up-stream’ pediatric health services as well as 
‘down-stream’ adult health services, between which there is often an inappropriate, sharp 
demarcation (Alriksson-Schmidt et al., 2014; Bjorquist et al., 2015; Nguyen et al., 2016; van 
Staa et al., 2011). Usually, there has been a multitude of measurements and interventions 
performed as part of the pediatric services for CP. Getting an overview of health and health 
problems right after the conclusion of childhood can help give feedback on the results of 
those actions. This information is also useful for adult health services, as identified emerging 
health issues can be addressed and managed early. The adult population with CP is very 
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large; while mortality is increased in individuals with CP with multimorbidity, most 
individuals will have a life expectancy similar to that of the general population (Himmelmann 
& Sundh, 2015; Reid et al., 2012; Touyama et al., 2013). 
The terms ‘adolescence’ and ‘young adulthood’ share common elements and have not been 
conclusively defined (Sawyer et al., 2018). However, for reasons of consistency in this thesis 
adolescence will be defined as the period in life between puberty and legal adulthood, and 
young adulthood as the first years of legal adulthood. 
1.2.4.1 Social aspects 
Social well-being is an integral part of the WHO definition of health (World Health 
Organization, 1946). What constitutes well-being in this sense is a matter of personal and 
environmental factors, cultural standards, and expectations (World Health Organization, 
1997). Qualitative research approaches have found that youth with CP and other chronic 
disorders rank social inclusion (Lindsay, 2016), relationships (Bjorquist et al., 2015), gaining 
independence from the parental family (Bjorquist et al., 2015; Nguyen et al., 2016) and 
moving away from the parental family (Tornbom et al., 2013) as desirable goals when 
transitioning from childhood to adulthood. Research has been scarce as to what degree goals 
such as these have been achieved, and perhaps more importantly, if there are particular 
factors that enable or disable the individual from reaching them.  
One of the first available reports on this topic was, interestingly enough, from the Stockholm 
area and the Karolinska Hospital (Avignon & Gardestrom, 1958). Data on health and social 
situation were gathered on children and young adults with CP. One main conclusion was that 
many of the respondents risked social exclusion due to lack of employment opportunities. 
Subsequent later studies from Denmark, in the 2000’s, found that adults of all ages with CP 
were to a lesser extent employed, in tertiary studies, living independently and/or cohabiting 
with partners, than the population as a whole (Michelsen et al., 2006; Michelsen et al., 2005). 
Findings along the same line were reported from clinic-based studies conducted in the 
Netherlands and the United States (Donkervoort et al., 2009; Murphy et al., 2000; van der 
Slot et al., 2010; Wiegerink et al., 2010). The studies found that cognitive function played a 
large part in determining social outcomes, while motor functioning appeared to have had a 
minor role. Conducted mainly on samples of individuals in wide age ranges, the specific 
situation in young adulthood remained to be further investigated, especially in a Swedish 
contexta. 
 
a Please note that the studies, including from Sweden, which have been published on this subject after the start 




1.2.4.2 Health status 
Similar to social aspects, the health status of individuals with CP after childhood was to a 
large extent unknown due to limited attention in research. Reports emerging in the 1990’s and 
2000’s on adults with CP of all ages noted that pain and fatigue were prevalent and that these 
issues appeared to become more troublesome in adulthood (Jahnsen, Villien, Aamodt, et al., 
2004; Jahnsen et al., 2003; Murphy et al., 1995; Sandstrom et al., 2004; van der Slot et al., 
2012). Fatigue can be described as experiencing feeling weak, tired, or lacking energy 
(McPhee et al., 2017). Fatigue has been recognized as a particularly debilitating co-morbidity 
in other conditions involving central nervous system dysfunction, such as adult stroke 
(Radman et al., 2012) and multiple sclerosis (Flachenecker et al., 2002). Overall health status 
(or HRQoL) for adults with CP has been reported as reduced in regards to physical 
functioning when compared to population norms, but not reduced in regards to self-reported 
mental health (Opheim et al., 2011; van der Slot et al., 2010). The situation specific to young 
adulthood remained inconclusive. Furthermore, it was noted that the health issues 
accompanying CP, such as pain and fatigue, were given too little attention (Baxter, 2013)a. 
1.2.4.3 Physical activity 
Physical activity is considered generally beneficial for most health parameters and CP is no 
exception. A meta-analysis (Ryan et al., 2017) of studies on exercise programs for individuals 
with CP have shown that exercise, especially aerobic or mixed programs, can improve gross 
motor function and participation in individuals with CP. Level of physical activity has been 
found to be inversely related with GMFCS-level (Bjornson et al., 2007; Maher et al., 2007). 
However, physical activity is possible also for individuals with more severe motor limitations 
using techniques such as RaceRunning (Hjalmarsson et al., 2020) and aquatic therapy (Lai et 
al., 2015). 
1.3 SPASTICITY, PAIN, AND ASSOCIATED TREATMENTS 
1.3.1 Spasticity 
The most common clinical sub-types of CP (Sellier et al., 2016); spastic unilateral CP and 
spastic bilateral CP (see Figure 1), are, from a movement-and-posture perspective, clinically 
characterized by elements of the so-called upper motor neuron syndrome (Kandel et al., 
2013; Purves et al., 2004)b. The underlying pathology is typically injury or dysfunction of the 
neurons of primary motor cortex or of their corticobulbar or corticospinal projections (Sanger 
et al., 2003). Salient features of this concept are weakness, reduced selective motor control, 
spasticity, and secondary musculoskeletal changes. (Note that other dysfunctions are 
sometimes included, such as hyperreflexia, and retained developmental reflexes). Weakness 
is “the decreased ability of the muscle to generate voluntary force” (Sanger et al., 2006). 
 
b Although the term ‘upper motor neuron syndrome’ is often used; especially in medical training for matching 
clinical neurological signs to neuroanatomical lesions, some neuroscientists advise against its use, deeming it a 
too simplistic view of the primary motor cortex (see Kandel et al, 2013) 
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Reduced selective motor control is “the impaired ability to isolate the activation of muscles in 
a selected pattern in response to demands of a voluntary posture or movement” (Sanger et al., 
2006). Secondary musculoskeletal changes involve alterations in the molecular and 
histological architecture of skeletal muscles, impaired muscle growth, and joint contracture 
development (Lieber et al., 2004; Mathewson & Lieber, 2015). Spasticity is, as apparent, only 
one component of the movement impairments but has been given a prominent role possibly 
due to it being a conspicuous feature. Although spasticity is a common clinical sign and 
symptom, there is no universally accepted definition (Malhotra et al., 2009). One of the most 
commonly used definitions is that of Lance (Lance, 1980): “a motor disorder characterized by 
a velocity-dependent increase in the tonic stretch reflexes with exaggerated tendon jerks, 
resulting from hyperexcitability of the stretch reflex”. A second definition, put forth by an 
interdisciplinary task force on the definition of childhood motor disorders include muscle 
hypertonia (itself defined as “resistance to passive stretch while the patient is attempting to 
maintain a relaxed state of muscle activity”) together with one or both of the following signs: 
“1) resistance to externally imposed movement increases with increasing speed of stretch and 
varies with the direction of joint movement, and/or 2) resistance to externally imposed 
movement rises rapidly above a threshold speed or joint angle” (Sanger et al., 2003). 
Recurring themes of spasticity are (oversimplified for visualization purposes): 1) stiff 
muscles and 2) muscles that become stiffer when stretched quickly. How to actually measure 
this stiffness or resistance to passive stretch is a matter of considerable debate (Fleuren et al., 
2010; Lin, 2011; Malhotra et al., 2009; Willerslev-Olsen et al., 2013). 
Although spasticity is a conspicuous clinical feature of many individuals with CP, and 
although therapies and interventions aimed at alleviating spasticity have taken prominent 
positions in the management of individuals with CP, the actual effect of spasticity on 
functioning in individuals with CP has been estimated to be limited. The fact that the 
definition is debated and how to objectively measure spasticity is disputed adds complexity 
when trying to disentangle the relative contributions of, for example; weakness, reduced 
selective motor control and spasticity on the functioning of the individual. Gorter and 
colleagues found a very limited relationship between spasticity and gross motor development 
in toddlers with CP (J. W. Gorter et al., 2009). Kim and Park performed a path analysis study 
of data on muscle strength, spasticity, gross motor function and functional activity in children 
with CP and found that strength was more associated with gross motor function than 
spasticity, but that neither were associated with functional activity (Kim & Park, 2011). 
Damiano and colleagues studied the resistance to stretch as performed by a mechanical 
device (as a measurement of spasticity) and the relationships between this with gait 
parameters. They found no correlation between the amount of resistance with gait parameters, 
although a subset of children whom had undergone selective dorsal rhizotomy (SDR) to 
relieve spasticity had gait changes that could imply a causal relationship with spasticity 
(Damiano et al., 2006). Noble and colleagues investigated the relationship between selective 
motor control (SMC) and gross motor function and spasticity in youth with CP: SMC was 
more strongly linked to gross motor function than spasticity was (Noble et al., 2019). Earlier, 
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Lin and Brown found no relationship between clinically assessed spasticity with toe-walking 
in children with spastic unilateral CP (Lin & Brown, 1992). Thus, it appears that the 
connection between spasticity and function is far from strong. 
Spasticity has traditionally often been implicated as the primary cause behind the 
development of contractures (Graham & Selber, 2003). Contractures appear when the 
muscle-tendon-complex length is shorter than needed for full range of motion of the joint it 
passes (Mathewson & Lieber, 2015). This can result from either the shortening of a 
previously adequately long muscle, or, as can be the case in a growing child, the 
inappropriate growth of a muscle. In CP, spasticity has been blamed for this, theorizing that 
stiff and over-reactive muscles kept the joints in question flexed and unrelaxed, thus 
inhibiting growth (Graham & Selber, 2003). This causality is still a widespread belief despite 
evidence of the contrary. In a long-term follow-up of children with CP treated with injections 
of botulinum toxin-A (BoNT-A) it was found that while spasticity was reduced, joint range of 
motion (ROM) continued to decline (Tedroff et al., 2009). Using a randomized controlled 
design, BoNT-A was used to reduce spasticity in the adductor muscles in an attempt to halt or 
slow progression of hip joint displacement in CP, also without success (Graham et al., 2008). 
Paper III of this thesis adds evidence that a completely different modality of spasticity 
reduction (selective dorsal rhizotomy) also fails to prevent contracture development (Tedroff 
et al., 2011). Cloodt and colleagues recently reported on the relative associations of age, 
GMFCS-level, hamstring and gastrocnemius muscle length, and spasticity of the knee and 
plantar flexors on the presence of knee contractures in a large sample of Swedish children 
with CP (Cloodt et al., 2018). They found that spasticity in the knee flexors, but not plantar 
flexors, was modestly associated with knee contractures. Research into properties of the 
skeletal muscles in individuals with spasticity has revealed that the muscle itself has 
significant changes in its molecular and histological composition, including changes to the 
extracellular matrix and the number of stem cell-like satellite cells it holds; changes that make 
the muscle stiffer and less likely to grow as expected (Dayanidhi et al., 2020; Lieber et al., 
2004; Mathewson & Lieber, 2015). The radical change in neural activity to the muscle that 
occurs as a consequence of the brain injury or malformation is thought to set in motion these 
alterations in the muscle (Pingel et al., 2017), alterations which probably remain regardless of 
whether any clinically evident spasticity is treated or not. 
1.3.2 Treatment of spasticity 
The decision to treat spasticity is individualized and should be made on the basis of the extent 
to which it interferes with activities and participation, individual and family goals, and care, 
comfort and sleep, while keeping in mind the limitations stated in the previous section. 
Evidence-based treatment modalities that are often considered for spasticity in CP include the 
following (Novak et al., 2013):  
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• Botulinum toxin-A (BoNT-A). This neurotoxin is extracted from the anaerobic 
bacteria Clostridium botulinum (Mazzocchio & Caleo, 2014) c and given as 
intramuscular injections (Heinen et al., 2010). After uptake in the presynaptic 
terminal of the neuromuscular junction BoNT-A inhibits the release of acetylcholine 
causing dose-dependent paralysis of the target muscle with a transient effect 
(Mazzocchio & Caleo, 2014). It is a common first choice of therapy in focal 
spasticity (Blumetti et al., 2019). The therapeutic use and evidence base of BoNT-A 
are expanded on below. 
• Baclofen. A selective agonist of the gamma-aminobutyric acid(GABA)B-receptor 
(Rang et al., 2003) baclofen acts by inhibition of central nervous pathways, 
especially of interneurons in the spinal cord (Price et al., 1984). It is given either 
orally, or, as a continuous intrathecal infusion (intrathecal baclofen, ITB) by means 
of an implanted pump (Albright et al., 2006). It is mainly used to treat non-focal 
spasticity (Dan et al., 2010). 
• Selective dorsal rhizotomy (SDR). This is an irreversible neurosurgical procedure 
where spinal dorsal rootlets containing afferent excitatory nerve fibers from the 
proprioceptors of the muscle spindles are sectioned before entry into the dorsal horn 
of the spinal cord (Park et al., 1993; Smyth & Peacock, 2000). The aim is to abolish 
or reduce the hyperexcitable stretch reflex of spasticity (Smyth & Peacock, 2000). 
• Bensodiazepines. These substances potentiate the effect of GABA on GABAA-
receptors by binding to an accessory site on the receptor (Rang et al., 2003). The 
mechanism of action in spasticity is through inhibition of central nervous system 
pathways. Diazepam and clonazepam are examples of specific substances used for 
this purpose (Novak et al., 2013). 
In this thesis, particular attention is given to SDR (as the treatment evaluated in paper III) and 
BoNT-A (as the treatment evaluated in paper IV). 
1.3.2.1 Selective dorsal rhizotomy 
The history of the SDR procedure goes back to classical experiments on the corticospinal 
tracts performed by Sherrington in the late 19th century. Muscle hypertonia in cats, induced 
by interrupting the cerebrospinal tracts, was relieved when the lumbosacral afferent dorsal 
roots were cut (Sherrington, 1898). The technique was used to treat spasticity in humans in a 
report from 1911 (Foerster, 1911) and subsequently intermittently but overall rarely used, 
with a variety of techniques (Fasano et al., 1978; Privat et al., 1976), until it was popularized 
in the 1980’s (Enslin et al., 2019; Vaughan et al., 1991). It was popularized mainly for the 
treatment of lower-limb spasticity in CP; a feature of the clinical sub-type then referred to as 
 
c Of academic interest, the bacterial genus Clostridium contains a number of well-known human pathogens: 
besides C. botulinum as the causative agent of botulism, C. tetani causes tetanus, and C. perfringens can cause 
food poisoning and gas gangrene. They induce disease primarily through the toxins they produce; the tetanus 
toxin is structurally very similar to the botulinum toxin.  
 
 11 
spastic diplegia and now included in the sub-type spastic bilateral CP. Gaining widespread 
use, the procedure now most commonly involves selectively sectioning fascicles (or 
‘rootlets’) of the dorsal roots, from lumbar myotome level 2 (L2) to sacral myotome level 1 
(S1), based on the electromyographical (EMG) appearance of intraoperative stimulation of 
each fascicle (Enslin et al., 2019). The dorsal roots are accessed either by a laminotomy of 
spinal levels L2-L5 (the “Peacock technique” (Smyth & Peacock, 2000)) where the fascicles 
are manipulated and severed close to the foraminae, or through a narrow laminotomy 
exposing just the conus medullaris (the “Park technique” (Park et al., 1993)). The post-
operative immobilization has varied between resumption of physical activities on 
postoperative day three, to being confined to six weeks in a spinal plaster (Enslin et al., 2019; 
Park et al., 1993). Adverse events in the short-to-intermediate term include sensory deficits 
and bladder control issues (McLaughlin et al., 1998; Nordmark et al., 2008; Park et al., 1993; 
Tedroff et al., 2011), unexpected falls (Grootveld et al., 2016) and a high frequency of spinal 
complications such as scoliosis, hyperlordosis and spondylolisthesis (Tedroff et al., 2020). 
There is also concern about the safety in the long-term given that so much sensory input, 
including proprioception, has been severed by the procedure.  
As it was found that the procedure markedly reduced spasticity it was, by the nature of the 
assumptions that spasticity was the main culprit behind functional limitations and contracture 
development, assumed that the procedure would indirectly result in better functioning and 
prevent contracture development in individuals with CP. A meta-analysis from 2002 
(McLaughlin et al., 2002) of three randomized controlled trials (RCT) (McLaughlin et al., 
1998; Steinbok et al., 1997; Wright et al., 1998) in children with CP remain the primary 
evidence-base for the efficacy of the procedure. The meta-analysis found that SDR clearly 
reduced spasticity in the children in all three included studies (McLaughlin et al., 2002). 
However, the effect on gross motor function: a mean difference between groups of 4.5 
percentage points on the Gross Motor Function Measurement, original version (GMFM-88) 
(Russell et al., 1989) and 2.7 points on the updated version (GMFM-66) (Russell et al., 2000) 
was less clear, with the authors stating that “these modest improvements in gross motor 
functioning are somewhat disappointing” and that “it is difficult to know the clinical 
importance of a mean difference in change score of 4 percentage points on the GMFM” 
(McLaughlin et al., 2002). The main limitation of the underlying RCTs was, from a clinical 
utility perspective, that they only had short-term follow-up (between 9 months and 2 years). 
The long-term effect on spasticity, gross motor function and contracture development needed 
further investigation. 
1.3.2.2 Botulinum toxin-A use in cerebral palsy 
The use of BoNT-A for spasticity in children with CP began in the 1990’s and has since 
gained widespread use. It was noted early on that the implementation of the procedure 
quickly surpassed the scientific evidence-base supporting its use (Forssberg & Tedroff, 
1997). Consensus papers on its use have since been published regarding children with CP 
(Heinen et al., 2010) and to some extent adults with CP (Esquenazi et al., 2010). There are 
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Cochrane Systematic Reviews that evaluate the effectiveness and evidence-base of BoNT-A 
use in the upper (Hoare et al., 2010) and lower extremities (Blumetti et al., 2019) in children 
with spastic CP. The 2010 review of its use in the upper extremities concluded that there was 
a high level of evidence that a combination of BoNT-A and occupational therapy (OT) was 
better than OT alone in reducing spasticity, improving activity level outcomes and goal 
achievement, but, that BoNT-A alone was ineffective (Hoare et al., 2010). The 2019 review 
of BoNT-A use in the lower extremities found that there was limited evidence that BoNT-A 
was more effective in reducing spasticity and improving gait, ROM and satisfaction as 
compared to placebo (Blumetti et al., 2019). Results on gross motor function were 
contradictory (Blumetti et al., 2019). Here, the quality of the evidence was considered low to 
very low, despite including 31 studies with a total of 1508 participants. 
Botulinum toxin-A has also been used in the control of excessive drooling (Walshe et al., 
2012), and has been tested as a treatment for pain in children with spastic CP in certain 
situations (Barwood et al., 2000; Lundy et al., 2009), which will be expanded on in the next 
section. 
During much of its use, BoNT-A has been considered a safe and fully reversible treatment 
with the effect diminishing over a few months. However, there are advocates for a more 
cautious use of BoNT-A. Concerns have been raised regarding long-standing negative effects 
on muscle strength and muscle composition, which could be irreversible (Alexander et al., 
2018; Gough et al., 2005; Multani et al., 2019). 
1.3.3 Pain in cerebral palsy 
As a co-morbidity of CP, pain has only fairly recently become a focus for systematic 
evaluation. In adults, in the US, Turk and colleagues performed a clinic-based survey in 1997 
amongst women with cerebral palsy of all adult ages and found that 84% reported bodily pain 
(Turk et al., 1997). In 1999, Schwartz and colleagues conducted a face-to-face study 
interviewing adults in the state of Washington, focusing on pain and pain interference 
(Schwartz et al., 1999). Sixty-seven percent reported one or more areas of chronic pain, 
however the interference pain had on daily activities was low. In adults in Scandinavia, 
Andersson and Mattsson had items on pain in their Swedish mailed survey from 2001 where 
48% reported muscle and joint pain at least once a month (Andersson & Mattsson, 2001). 
Jahnsen and colleagues highlighted the problem of persistent pain in their 2004 Norwegian 
survey of adults with spastic CP. They reported a prevalence rate of about 30% of the adults 
reporting chronic pain, with an increasing trend with age (Jahnsen, Villien, Aamodt, et al., 
2004). Both overexertion and inactivity were common self-reported triggers and/or causes of 
pain. In follow-up studies on this Norwegian cohort of adults with CP, it was shown that pain 
and fatigue were correlated to deterioration in walking (Opheim et al., 2009) and that pain 




Pain came even more into the spotlight in a 2012 systematic review on clinical issues 
accompanying CP (Novak et al., 2012). Their results were that 75% of the entire population 
with CP suffered from pain, which in turn triggered a debate on whether pain was under-
diagnosed and under-treated in CP (Baxter, 2013). A systematic review on pain in children 
and young adults with CP from 2019 noted that pooling the data from existing studies was 
not easy due to sampling bias and differing methodology (McKinnon et al., 2019). Their 
results were that 14-76% in the study population had pain and that risk factors were female 
gender, increasing age, and being classified in GMFCS level V (McKinnon et al., 2019). 
Different mechanisms causing pain have been proposed and these include over-use and 
excessive strain on disabled limbs (Murphy et al., 1995), pain worsening during certain 
aspects of physiotherapy (Parkinson et al., 2013), and pain caused by dystonia (Penner et al., 
2013) and hip subluxation (Penner et al., 2013). Spasticity has often been implied as a cause 
of pain, both by clinicians and researchers and not least by individuals with CP themselves, 
but the systematic literature on this is fairly scarce (Blackman et al., 2018). Flanigan and 
colleagues recently found correlations between pain intensity with both spasm frequency and 
spasticity in adults with CP (Flanigan et al., 2020). 
1.3.4 Treatment of pain in cerebral palsy 
The evidence base for the management of pain in CP is poor. An attempt (2019) at a 
systematic review for pain management in children with CP had to resolve to narrative 
synthesis instead of meta-analysis due to a high risk of bias in included studies, and could 
only make recommendations for a few specific clinical situations (e. g. children whom were 
candidates for ITB, and postoperative situations) (Ostojic et al., 2019). The review stressed 
that further research was needed especially in the area of chronic pain (Ostojic et al., 2019). 
There are no published RCTs in adults with CP with pain reduction as the primary objective 
prior to our study. Finding treatments addressing chronic pain in adults with CP is a major 
priority, as pain appears to worsen with age (McKinnon et al., 2019). 
1.3.4.1 The potential use of botulinum toxin-A  
Botulinum toxin-A has been tried and reported in a few specific circumstances as an 
analgesic in children with CP. Lundy and colleagues reported a case series of children in 
GMFCS level V whom had spasticity and pain at the hip level. The children, all treated with 
BoNT-A, reported a decrease in pain (Lundy et al., 2009). Barwood and colleagues 
performed an RCT where BoNT-A was compared to placebo in children with spasticity at the 
hip level who underwent adductor tenotomy. They found significant pain reduction and 
reduction of hospital stay for the BoNT-A group (Barwood et al., 2000). Recently, however, 
Will and colleagues found no difference in pain when comparing BoNT-A to placebo in a 
similar perioperative setting but where the children underwent bony hip surgery (Will et al., 
2019). 
Botulinum toxin-A has found use in pain conditions that are unassociated with muscle 
overactivity. For example, it has a proven effect on chronic migraine (Herd et al., 2018), post-
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herpetic neuralgia (Safarpour & Jabbari, 2018) and trigeminal neuralgia (Safarpour & 
Jabbari, 2018). Besides the direct actions BoNT-A has on muscle activity (reducing muscle 
tone and decreasing spasms) through the inhibition of presynaptic acetylcholine release, it 
also appears to block neurotransmitter and neuropeptide release from nociceptive nerve 
endings (Mazzocchio & Caleo, 2014; Ramachandran & Yaksh, 2014). This combined mode 




2 AIMS OF THE THESIS 
The overall aim of this thesis was to better understand the health status and social situation of 
young adults with cerebral palsy and to evaluate specific treatments for spasticity and pain. 
The specific aims of the studies were as follows: 
I. To describe a set of social outcomes in young adults with CP and to explore 
associations between these outcomes and the young adults’ level of gross motor 
function, manual ability, communication function, and presence of intellectual 
disability. 
 
II. To describe health-related quality of life, pain, and fatigue in young adults with CP 
and to explore associations between these variables and the young adults’ level of 
gross motor function and level of physical activity. 
 
III. To describe the long-term outcome after selective dorsal rhizotomy in children with 
CP, with a focus on the effect on spasticity, gross motor function, and contracture 
development. 
 
IV. To test if botulinum toxin-A is effective in reducing chronic muscle-related pain in 







3.1 GENERAL STUDY DESIGNS 
The following methods were used in order to answer the research aims for each paper 
respectively: 
• Papers I and II used a cross-sectional study design. 
• Paper III used a case series study design. 
• Paper IV used a randomized, double-blinded, placebo-controlled study design. 
The different study designs carry with them different possibilities and limitations, which are 
worth a brief review. 
3.1.1 Cross-sectional studies 
A cross-sectional study describes a group of subjects at a particular point in time(Campbell, 
2007). It can describe the proportion of individuals within the group with a particular 
characteristic and analyze how that characteristic varies by other variables in the group, such 
as age or gender. Cross-sectional studies allow hypothesis testing of whether different 
characteristics are positively associated (i. e. tend to be present together) or negatively 
associated (i. e. tend to not be present together) These associations can be quantified through 
for example correlational analyses, but the study design does not in itself permit establishing 
causality. 
3.1.2 Case series 
A case series is typically a study that follows a group of individuals with a similar exposure, 
such as a particular treatment, over time in order to describe their outcome (Dekkers et al., 
2012). It can also refer to a group of individuals with a particular (and rare) diagnosis who are 
studied to determine the course of their disease. The method is one of the few ways to 
perform research on rare diagnoses or rare treatments. It is distinct from a cohort study, which 
starts with a sample of exposed and unexposed individuals and follows them over time to see 
which ones get the outcome, usually involving a very large sample (Dekkers et al., 2012). A 
case series is a type of descriptive study and not generally meant for hypothesis testing. Any 
change in the outcome over the course of the time can, however, be subjected to statistical 
testing to see whether the change could be attributed to random chance or not. 
Consecutive case series are preferred over non-consecutive series as the latter involve the risk 
of excluding individuals with unfavorable outcomes (selection bias). 
3.1.2.1 Note on Paper III 
At the commencement of the SDR-study in 1993, it was intended as an RCT with three 
treatment arms: SDR + standard care, orthopedic surgery + standard care, or standard care 
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alone. As allocation to anything other than SDR proved difficult for families to accept, the 
study turned into a consecutive case series of children undergoing SDR. 
3.1.3 Randomized controlled trials 
The randomized controlled trial (RCT) is the study design which offers the best possibility to 
establish causality. By randomly allocating subjects to the different treatments under 
investigation much of the bias inherent to observational studies can be avoided, most notably 
the unmeasured or unknown bias (Campbell, 2007). Preferably, the allocation remains hidden 
to the patient and the investigator (double blinding) in order to avoid conscious or 
unconscious preconceptions. Positive expectations or negative expectations on a treatment 
will have powerful effects on the outcome as has been shown in many different scenarios in 
the field of placebo research (Benedetti et al., 2015; Benedetti et al., 2014; Jensen et al., 2012; 
Kaptchuk et al., 2006). 
3.2 PARTICIPANTS 
All four papers in this thesis exclusively include individuals with a diagnosis of CP. All 
participants have given informed oral and written consent, either themselves directly or 
through their legal proxies. All studies were approved by the appropriate Ethical Review 
Board. An overview of the participants is given in Table 1.  
Table 1. An overview of participant characteristics 










I & II 61 21 y, 2 m  
(8 m) 
27 (44) 2013-2016 
III 19 4 y, 7 m  
(1 y, 7 m) 
4 (21) 1993-2007 
IV 16 32 y  
(13 y) 
10 (63) 2015-2018 
N: Number. SD: Standard deviation. y: years. m: months. 
Papers I and II had joint data collection. There were only a few occasions where one 
individual participated in more than one data collection: three individuals whom had taken 
part in the SDR follow-up (Paper III) also participated in Papers I and II, and five individuals 
whom had participated in Papers I and II participated also in Paper IV.  
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Other than a diagnosis of CP, inclusion and exclusion criteria differed between data 
collections to accommodate the study aim. The criteria are detailed in Table 2. 
Table 2. Inclusion and exclusion criteria 
Paper Inclusion criteria Exclusion criteria 
I & II • Diagnosis of CP registered at a 
Stockholm county clinic 
• Age ~ 21 y (born 1992-1995) 
• None 
III • Spastic diplegic CP 
• Age 2 – 9 y 
• Normal or only mildly impaired 
cognitive development 
• Some method of independent 
locomotion 
• Significant spasticity in the 
lower extremities with a slow 
increase or plateau in gross 
motor development ≥ 6 months 
• Major rigidity, dystonia, 
dyskinesia, ataxia or 
hypotonia 
• Marked weakness in 
antigravity muscles 
• Fixed joint contractures 
• Previous surgery such as 
osteotomies, tendon 
lengthening or neurectomy 
IV • Age ≥ 18 y 
• Spastic sub-type of CP 
• Chronic pain related to spastic 
muscle 
o ≥ 3 months duration 
o ≥ 3 in pain intensity on 
NRS 
 
• Hypersensitivity to BoNT-A 
• Pregnancy or breastfeeding 
• Treatment with BoNT-A 
within the last 5 months 
• Changes in muscle tone 
altering drugs within the last 2 
weeks 
• Degenerative pain etiology 
• Intellectual disability and/or 
communication limitation  
BoNT-A: Botulinum toxin-A. CP: Cerebral palsy. NRS: Numerical rating scale. y: years. 
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3.2.1 Methods for inclusion 
3.2.1.1 Papers I & II 
The approach for finding and including participants in a cross-sectional study varies. The 
goal should however always be to try to include a sample of individuals whom truly represent 
the population of interest. The target population in this data collection was young adults, 
within a narrow age-span, with CP within a geographical area reasonably available to the 
research team. The individuals in this population were located based on a few assumptions: 1) 
they should have had at least one visit to any one of the clinics in the Stockholm county 
serving children and adolescents with CP within the last five years, 2) the medical record 
from the visit(s) should contain the ICD-10 diagnosis code for CP, and 3) they should hold a 
Swedish personal identity number. It was considered that this approach reasonably should 
include most if not all of the target population, and that the inclusion approach itself therefore 
could be referred to as population based.  
3.2.1.2 Paper III 
All children whom underwent SDR at the Karolinska University Hospital, Stockholm, 
Sweden from the time when the procedure was established (1993) to the time when the 
procedure was largely discontinued (after 1997) were invited to participate in the follow-up 
study. 
3.2.1.3 Paper IV 
Multiple ways of reaching adults with spastic CP and muscle-related pain were used. This 
was based on the knowledge that health care for adults with CP is mostly decentralized and 
uncoordinated in the Swedish health care system. It was assumed that potential participants 
could be found in various environments: in a few specialized clinics, in rehabilitation centers, 
in patient-advocacy groups, in the group of young adults participating in the first two studies 
of this thesis, and in society as a whole. Therefore, information was sent out to these health 
care institutions and advertisements were placed in journals and the general press.  
3.3 SPECIFIC ASPECTS OF THE DESIGN AND THE DATA COLLECTION 
The papers in this thesis share a characteristic in regards to the data collection: information 
was collected through direct contact with the study participants (as opposed to mailed 
surveys, or collection exclusively through chart reviews). For papers I, II and IV the author 
was the primary investigator. 
3.3.1 The cross-sectional studies 
The process of making contact with the young adults, arranging the visit, and collecting the 
data was laborious. The primary incentive for the young adults to participate was solely to 
contribute to the scientific knowledge within the field; the visit was not a formal health-care 
visit although any medical issues which arose were given appropriate evaluation and 
necessary referral. The visits had to be arranged as to not collide with other scheduled 
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activities for the young adult, and so that the appropriate proxy could attend in the case of 
communication limitations. 
 
Image 1. Snapshot of the data collection. With permission from the participant. 
The data collection took place as an on-site visit to the Astrid Lindgren’s Children’s Hospital 
at the Karolinska University Hospital, Solna (Image 1). Here, the young adult and any 
accompanying family members or personal assistants met with the author as the primary 
investigator and one of two specialized physiotherapists as co-investigators. The visit often 
lasted half a working day and included short breaks. Only a minority (20%) participated 
through telephone. Telephone participation required the same or more time to complete the 
data collection, as this required additional chart reviews to retrieve clinical data. The data 
collection was extensive and included more variables than those presented in this thesis. 
All participants received a small gift of gratitude (the young adults’ choice of movie theater 
vouchers or vouchers for a clothing store). 
3.3.2 The selective dorsal rhizotomy case series 
Follow-up of after the SDR procedure was performed at six months, twelve months, eighteen 
months and then yearly. As with the other data collections in this thesis, the visit took place 
as a specifically dedicated, on-site, multidisciplinary evaluation, lasting half a day. It is thus 
not a retrospective combination of chance visits to the center or other centers, but a 
specifically purpose-designed follow-up. 
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3.3.3 The randomized controlled trial 
Paper IV is an academically initiated and academically funded randomized controlled trial 
free from involvement of any entity with a commercial interest in the pharmaceutical product. 
This means that all stages of the trial were managed by the authors; design, study protocol, 
case report forms, applications to regulatory authorities and ethical committees, clinical visits, 
hosting inspections, analysis of the data, and writing reports and the manuscript. While 
requiring considerably more time and effort than an industry-sponsored clinical trial, the risk 
of bias introduced by economic interests is avoided (Lundh et al., 2017). The study was 
continuously monitored (inspected) for adherence to the study protocol and all regulations by 
the independent organization Karolinska Trial Alliance. 
3.3.3.1 Interim analysis 
Paper IV included, by design, an interim analysis. This analysis was incorporated into the 
study for one main reason: to avoid exposing people to experimental treatments if it was 
shown to be unnecessary. The interim analysis was thus of the type called stop for futility and 
meant that it should be stopped if calculations performed roughly half-way through the study 
were to show that the probability to achieve success on the primary outcome was less than 
twenty percent. These evaluations were performed by an independent Data Monitoring 
Committee (DMC) consisting of hired statistical and medical expertise.  
The use of such an interim analysis was motivated by the fact that there were no formal 
preceding pilot trials. It was therefore necessary to make assumptions regarding the expected 
efficacy of the active treatment as well as any placebo responses, as well as the expected 
time-to-effect of the treatment (see also Sample size below). Other than the obvious goal of 
protecting study participants from unnecessary experimental treatment, the interim analysis 
can also be said to serve a dual purpose in the usefulness of the study. In the primary scenario 
where the interim analysis does not recommend a termination of the trial, the study can run its 
course and fulfill the confirmatory purpose. In the scenario were the DMC recommends stop 
for futility, the study can serve as a pilot trial for future confirmatory trials. 
3.4 SAMPLE SIZE 
Papers I, II and III were all exploratory in their design and did not therefore involve 
prespecified differences to detect (in contrast to a confirmatory study). Hence, no formal 
sample size calculation was performed for these studies. For papers I and II, the aim for the 
sample size was to maximize inclusion within the limits of the inclusion criteria (as larger 
samples give more precise estimates) and to aim for good generalizability through the 
population-based inclusion approach.  
For the case series in paper III the sample size itself was not the primary aim. It would be 
questionable to promote surgery for the sake of sample size. The primary aim concerning 
inclusion was to maintain a consecutive case series. 
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Paper IV was a hypothesis-testing study with a pre-specified primary endpoint and thus relied 
on sample size calculation. This requires determining what difference one wants to detect: if a 
very small difference in between groups is what you expect to find or are satisfied in finding, 
then you need a large sample size to detect it. If on the other hand you only consider a large 
difference to be meaningful to find, you only require a smaller sample. In the case of this 
study, with BoNT-A treatment being compared to placebo treatment, there are several 
arguments that point out that only a large difference is worth finding: 
1) BoNT-A is expensive: both the drug itself and the fact that the administration of it 
requires clinic time and resources and skilled practicioners (as opposed to, for 
example, pills you take at home). 
2) The treatment itself involves procedural pain. Soreness is not uncommon in the days 
following treatment. 
3) The treatment goal is reduction of pain, which is a ‘softer’ endpoint than for example 
reduced mortality or a reduction of disability. For example: if a study shows that if 
you treat 67 patients with a drug you save the life of one individual (Shakur et al., 
2010) (numbers needed to treat (NNT) = 67), it is likely to be considered a valuable 
treatment. However, a study where the outcome was that one in 67 patients 
experienced reduced pain is likely to be considered ineffective. 
4) Established analgesics for chronic pain have NNT values somewhere around 2 – 10 
(Derry et al., 2016; Finnerup et al., 2015). Given the relative inconvieniences of 
BoNT-A, the desired NNT should be in the lower part of that interval. 
The primary endpoint was the proportion of treatment responders, defined as a reduction of 
pain intensity of ≥ 2 on the NRS as compared to baseline, at six weeks after treatment. The 
study was designed to detect a difference in the primary endpoint of 40%, i. e. a 70% 
proportion of responders in the BoNT-A group compared to a 30% proportion of responders 
in the placebo group. This corresponds to an NNT of 2.5.  
Before determining a sample size, the appropriate level of risk for making a type 1 error and a 
type 2 error must be selected. A type 1 error is the rejection of a true null hypothesis; i. e. a 
false positive. A type 2 error is the non-rejection of a false null hypothesis; i. e. a false 
negative. False positives are generally considered more dangerous than false negatives. These 
risks are realities: eliminating them would require huge and impractical sample sizes. A 
common practice in medical research is therefore to set the risk of a type 1 error to 5% (a = 
0.05) and the risk of a type 2 error to 20% (b = 0.20) (Campbell, 2007). The power to detect a 
true difference (often referred to as the ‘statistical power’) is therefore often 1 – b or 80%. 
With a = 0.05 and 1 – b = 0.80 the sample size for paper IV is calculated to be n=42, 
meaning 21 individuals per treatment arm.  
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3.5 VARIABLES AND OUTCOME MEASURES 
This section will expand on the variables and outcome measures that were used in the papers. 
These are presented by the field of interest they relate to.  
The common clinical descriptors of individuals with CP; the clinical sub-type and the 
GMFCS level (and the MACS level and CFCS level) are described in section 1.1.2 in the 
Introduction. 
3.5.1 Social outcomes 
This is one of the methodologically more challenging parts of the thesis. There is no 
universally accepted measurement for social outcomes or social participation. Most studies 
within this field have used in-house constructed items (Andersson & Mattsson, 2001; Benner, 
Hilberink, Veenis, van der Slot, et al., 2017; Michelsen et al., 2006; Michelsen et al., 2005; 
Reddihough et al., 2013) based on common themes of participation from the ICF concept 
(World Health Organization, 2002), while others have used specific surveys or instruments 
such as specific sections of the Vineland Adaptive Behavior Scales or the Life Habits 
questionnaire (Tan et al., 2016; van der Slot et al., 2010; van Wely et al., 2020). The social 
outcomes measured in paper I were in-house constructed items developed using a multi-
modal approach. The choice was motivated in part by the fact that simple yes or no questions 
on easily understandable items, such as Have you moved away from home, are more 
intuitively informative than a ‘participation score’. The first step in defining the outcomes 
was to scrutinize published literature on the social situation of adults with CP and to, if 
possible, use similar items as to be able to compare outcomes between different studies and 
populations. Questions which adolescents with CP and their families frequently asked in the 
clinic were also considered. Before implementation, volunteer pilot participants (young adults 
with CP known to the research group) were interviewed using drafts of the study protocol and 
gave feedback on the validity and categorization of the items.  
The final items referred to whether the young adult had: 
• Moved away from the parental home 
• An intimate relationship, past or present 
• Friends with whom they socialized with outside of the home including on evenings 
• An occupation, specified as 
o Regular (competitive) employment 
o Higher education (university/college) 
o Vocational studies or adult high school 
o Wage-subsidised employment or activity programs 
o Activity programs for individuals with ID 
o No occupation or activity 
• Personal finances that were 
o Independent  
o Dependent on the parental family 
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o Dependent on government subsidies 
• Need for support, by parental family members, with activities of daily living (ADL)  
3.5.1.1 Comments on the social outcomes 
There were originally more items on friends and socialization. However, many young adults 
reported difficulties in reliably answering many of the items. The remaining item as defined 
above about socialization outside of the home including on evenings could however be 
reliably answered as assessed both by the participants and the investigators (the author and 
co-authors). This item is also found in the TRACE-study by Canadian investigators (J. W.  
Gorter & Punthakee, 2012) and in the Rotterdam Transition Profile developed in the 
Netherlands (Donkervoort et al., 2009). A general observation is that items need to be 
adjusted to the changing patterns of socialization online and in social media. 
The items mostly belong to the Participation component of the ICF (World Health 
Organization, 2013), while personal finances and family help with ADL can be sorted under 
Contextual factors. If instead the item on ADL was posed as “to what extent do you perform 
your ADL by yourself” it would belong to the Activities component. However, the intent was 
to explore the issue from the perspective of transition from parental-family-centered life to 
parental-family-independent life. 
3.5.2 Health-related quality of life 
The Short Form-36 version 2 (SF-36v2) (Optum, 2019; Ware & Sherbourne, 1992) was used 
to measure HRQoL. The SF-36v2 is a 36-item generic survey that is valid and reliable for the 
measurement of physical and mental health / HRQoL (Optum, 2019; Ware & Sherbourne, 
1992). The survey is administered as a questionnaire. The results of the questionnaire are 
processed in a software which produces scores on different health domains. 
The SF-36v2 software provides scores for eight health domains: Physical Functioning, Role-
Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and 
Mental Health. Two summary scores are also provided: The Physical Component Score 
(PCS) and the Mental Component Score (MCS). Norm-based scores (NBS) are most often 
used. These norms center on a score of 50, with 10 points corresponding to 1 SD. 
3.5.2.1 Comments 
The debate on the nomenclature for health status versus HRQoL (see Introduction, section 
1.2.3) is evident also in regards to this instrument. While some of the original developers of 
the SF-36 refer to it as “a set of generic, coherent, and easily administered quality-of-life 
measures” (Rand Corporation, 2020), the current copyright holder of the SF-36v2 refers to it 
as a “measurement of physical and mental health” (Optum, 2019).  
The EQ-5D is another generic instrument for measuring health status/HRQoL. The SF-36 and 
the EQ-5D are arguably the most common measurements for this purpose. The EQ-5D family 
of measurements include versions aimed at young respondents (Herdman et al., 2011; Wille 
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et al., 2010; Williams, 1990). The EQ-5D-3L is used in the Swedish Cerebral Palsy Follow-
Up Program (CPUP) (Jarl et al., 2019) but had not been used in a peer-reviewed publication 
from the CPUP at the time of the design of this thesis. The SF-36v2 was chosen in part 
because it has been used in previous studies on adults with CP (Jahnsen, Villien, Egeland, et 
al., 2004; Opheim et al., 2011; van der Slot et al., 2010) (where it was, as a side note, referred 
to as a measurement of HRQoL), which would allow for comparisons across populations.  
3.5.3 Fatigue 
The severity of fatigue is, similar to HRQoL and pain, a subjective patient-reported outcome 
(PRO). In this thesis the Fatigue Severity Scale (FSS) (Krupp et al., 1989) was used. The FSS 
is a questionnaire consisting of 9 items where the respondent is asked to rate on a 1 – 7 
ordinal scale the agreement with different statements regarding the personal experience of 
fatigue, for example (question 4): “Fatigue interferes with my physical functioning”. The 
result of the questionnaire is most often reported as the mean rating on these items. 
3.5.3.1 Comments 
The FSS has been used in many studies in adults with CP (Opheim et al., 2009; Russchen et 
al., 2014; Slaman et al., 2015; van der Slot et al., 2012). It is also the fatigue measurement of 
choice in the Swedish CPUP program for adults. Other instruments that have been used in 
adults with CP but to a lesser extent include the Fatigue Questionnaire (Jahnsen et al., 2003; 
Opheim et al., 2009), the Fatigue Assessment Scale (Sienko, 2018) and the Fatigue Impact 
and Severity SelfAssessment (McPhee et al., 2017). 
3.5.4 Pain 
The main measurements of pain in this thesis were the Numerical Rating Scale (NRS), the 
Brief Pain Inventory – Short Form (BPI) (Keller et al., 2004) and the Bodily Pain domain on 
the SF-36v2.  
The NRS is a simple 1-item question: “Please rate your pain by circling the one number that 
best describes your pain on the average in the last 24 hours” with the interval being 0 – no 
pain, to 10 – worst pain imaginable, with discrete single digit steps (Dworkin et al., 2005). 
The NRS can be a stand-alone item but it is also integrated in the BPI.  
The BPI is a 2-page questionnaire with a 24-hour recall period. It includes a simple template 
of the human body where pain localizations can be marked. The questions are divided into 
pain intensity, current treatment and efficacy, and pain interference. The respondent is asked 
to rate the intensity of pain or the interference pain imposes on the different items on a 0 – 10 
ordinal scale ranging from 0: no pain/no interference to 10: worst imaginable pain/completely 
interferes.  




The NRS has been recommended as the preferred method to measure pain intensity in 
research rather than the Visual Analogue Scale (VAS) (Dworkin et al., 2005).  
The BPI has been used in other studies involving individuals with CP (Flanigan et al., 2020; 
Sienko, 2018) and has been formally validated in this population (Tyler et al., 2002). The 
measure of pain interference is considered particularly useful and has made the BPI a 
recommended pain measure in clinical trials (Dworkin et al., 2005).  
3.5.5 Physical activity 
The Saltin-Grimby Physical Activity Level Scale (SGPALS) (Grimby et al., 2015) was used 
to measure habitual physical activity. It is a generic measure administered as a 1-item 
questionnaire. The scale is divided into four levels: 
• Level 1: Sedentary lifestyle. Being almost completely physically inactive; reading, 
watching TV, using computers/iPads/similar or doing other sedentary activities. 
• Level 2: Light-moderate physical activity. Some physical activity at least 4 hours per 
week as bicycling, walking, self-propelled mobility and similar. 
• Level 3: Regular strenuous physical activity. At least 2-3 hours per week of physical 
activity or training such as running, swimming, raquet sports, race-running and 
similar markedly heart-rate increasing activities. 
• Level 4: Regular hard physical activity for competition sports, several times per week. 
The scale was only slightly modified by adding examples of activities that apply to 
individuals with physical disabilities. 
3.5.5.1 Comments 
There is no well-established standard for measuring habitual physical activity in individuals 
with CP across the whole spectrum of motor functioning, a problem which has been 
highlighted in systematic reviews (Bloemen et al., 2017; Reedman et al., 2017; Ryan et al., 
2017). The SGPALS has a simple structure, which could be a strength, but it has with a few 
exceptions (Tedroff et al., 2015) not found wide use in CP. Wearable accelerometers are 
frequently used in research to measure habitual physical activity in ambulant individuals with 
CP. Accelerometers do however have limitations in measuring physical activity in individuals 
with limited ambulatory activity and cannot accurately measure, for example, swimming 
(Reedman et al., 2017). 
3.5.6 Gross motor function and mobility 
In paper III, the gross motor function was measured using the Gross Motor Function Measure 
(GMFM-88) (Russell et al., 1989). The GMFM-88 is a standardized observational assessment 
of motor capacity. Conducting a GMFM-88 measurement requires trained health 
professionals. It consists of 88 gross motor function items, which are scored on a four level 
ordinal scale (0 – does not initiate, 1 – initiates, 2 – partially completes, and 3 – completes) in 
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five areas of motor functioning: Lying and Rolling; Sitting; Crawling and Kneeling; 
Standing; and Walking, Running and Jumping. The results are reported as a percentage score 
on each gross motor area as well as a combined percentage score, where 100% is the 
expected capacity of a typically developed five-year-old child.  
Paper III also included a mobility scale, the Wilson Mobility Scale, a 1-item assessment 
comprising nine discrete levels of mobility functioning (Astrom & Soderhall, 2002), with 
level 1 describing “functional walking without aids in all surroundings” and level 9 
describing “sitting with support and no mobility”.  
3.5.6.1 Comments 
Further development of the GMFM-88 has led to the shortened GMFM-66 (Russell et al., 
2000) with derivatives.  
Other functional mobility assessments that have been used in the field of CP include the 
Functional Mobility Scale (FMS) (Graham et al., 2004) and the Gillette Functional 
Assessment Questionnaire (Novacheck et al., 2000). 
3.5.7 Spasticity 
Table 3. The Modified Ashworth Scale (MAS) according to Bohannon & Smith 
Grade Description 
0 No increase in muscle tone 
1 Slight increase in muscle tone, manifested by a catch and release or by 
minimal resistance at the end of the range of motion 
1+ Slight increase in muscle tone, manifested by a catch, followed by 
minimal resistance throughout the remainder (<50%) of the ROM 
2 More marked increase in muscle tone through most of the ROM, but 
easily moved 
3 Considerable increase in muscle tone, passive movement difficult 
4 Affected part rigid in flexion or extension 
ROM: Range of motion. 
In Papers I, II and IV in this thesis, the Modified Ashworth Scale (Bohannon & Smith, 1987) 
(Table 3) according to Bohannon and Smith was used to assess spasticity. In Paper III, the 
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Modified Ashworth Scale according to Peacock and Staudt (Peacock & Staudt, 1991) (see 
description under comments) was used. 
The MAS is assessed with the person being examined lying on his/her back and resting. The 
joint in question is then extended from maximal flexion to maximal extension, with the 
motion taking place in one second. 
3.5.7.1 Comments 
The Ashworth scale as modified according to Peacock and Staudt differs mainly compared to 
Bohannon and Smith by including hypotonia (marked as ‘0’) on the scale, with ‘1’ signifying 
normal muscle tone. This scale ranges from 0 – 5 (Peacock & Staudt, 1991). 
As expounded on in section 1.3.1 in the Introduction, there is considerable debate in regards 
to the definition and measurement of spasticity. The validity and reliability of the MAS has 
been questioned (Fleuren et al., 2010), particularly that presence of a contracture would 
confound the measurement (Patrick & Ada, 2006), but it nonetheless remains arguably the 
most common way of reporting spasticity. A recent systematic review and meta-analysis 
found satisfactory reliability (Meseguer-Henarejos et al., 2018). The MAS is the 
measurement used for spasticity in the Swedish CPUP program.  
Another common measure is the Modified Tardieu scale (Boyd & Graham, 1999; Tardieu et 
al., 1954), which emphasizes testing the resistance to passive stretch at different velocities 
(Haugh et al., 2006). This scale has also been the subject of methodological critique (Yam & 
Leung, 2006). 
3.5.8 Contractures 
The presence of contractures can be described by measuring the maximal passive joint range 
of motion (ROM) and using cut-off values for when a large enough deficit in ROM results in 
a deformity and/or functional limitation. Because contractures are often treated with tendon-
lengthening procedures in individuals with CP the extent of soft-tissue surgery can be used as 
a proxy measurement of contracture development. 
3.6 STATISTICAL METHODS 
The statistical methods for each part of the thesis are described in detail in the individual 
papers. Standard practices for descriptive statistics and analytical statistics were followed 
with consideration of whether the underlying data was nominal, ordinal, interval or ratio, and 
whether the assumptions for parametric or non-parametric tests were fulfilled. A conservative 
approach was used: if there was any doubt that the assumptions for a parametric test were not 
met, a more robust non-parametric test was used in its place. 
Regression models were preferred over Analysis of Variance (ANOVA) calculations when 
estimating the effect of multiple variables on an outcome in order to report the individual 
significances of each included variable.  
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4 RESULTS AND DISCUSSION 
In this section the results of the four papers are summarized and discussed. 
4.1 HEALTH AND SOCIAL OUTCOMES IN YOUNG ADULTHOOD 
4.1.1 Participant characteristics 
There were 189 individuals whom met the inclusion criteria for the data collection for papers 
I and II. Only 138 responded to communication attempts by mail or telephone, of which 61 
subsequently participated in the data collection. This corresponds to an inclusion of 32% of 
the target study population or 44% of those 138 whom could be reached. Table 4 outlines the 
proportions of levels of the GMFCS in this data collection with comparison populations. 
Table 4. Distribution of GMFCS level categorizations for the current sample with 
comparison populations. 






al., 2014), % 
ACPR, 
Australia 





al., 2018), % 
I 41 37 34 
67 
II 13 14 25 
III 11 11 12 6 
IV 15 8 13 
27 
V 20 15 16 
Note: Fifteen percent had unknown GMFCS classification level in the CPUP 
Adult Sweden population. 
GMFCS: Gross Motor Function Classification System. CPUP: Cerebral Pares 
UppföljningsProgram. ACPR: Australian Cerebral Palsy Register. CPRN: 
Cerebrale pareseregistret i Norge. 
The young adults in the current sample did not differ substantially from important 
comparison populations with regard to the distribution of GMFCS levels. The most important 
comparison is with the Swedish CPUP Adult population (Alriksson-Schmidt et al., 2014). 
The difference would be that the current sample includes a few more with lower motor 
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functioning. The distribution of sex (with a slight male predominance) is as expected (see 
paper I) and the prevalence of intellectual disability (46%) and epilepsy (34%) (Jacobson et 
al., 2019) is likewise not different from expected proportions (Novak et al., 2012). It can 
therefore be argued that the sample of young adults should be representative. 
4.1.2 Social outcomes 
Paper I gives a snapshot picture of social outcomes in young adults with CP, around 21 years 
of age, who have grown up in the larger Stockholm area. In summary: 
• 20% had moved out of the parental home 
• 20% were currently in an intimate relationship 
o 31% were not currently in a relationship, but had previously been so 
• 70% socialized with friends, outside home, including on evenings 
• 85% were in an occupation, whereof 
o 18% were in regular (competitive) employment 
o 16% were in higher education 
o 5% were in vocational studies or adult high school 
o 5% were in wage-subsidised employment or activity programs 
o 41% were in activity programs for individuals with intellectual disability 
• Personal finances were classified as 
o 30% had independent personal finances 
o 39% were dependent of government subsidies 
o 31% were dependent on the parental family 
• 43% needed support from parental family members, day and night, with ADL 
Five of these variables were further analyzed to detect whether being in levels I-II or III-V on 
the GMFCS, MACS and CFCS respectively, or having ID, made any difference on the 
outcome. The variables were  
1) Having moved away from the parental home  
2) Presently being or previously having been in an intimate relationship  
3) Being in regular employment and/or in higher education  
4) Having independent personal finances  
5) Socializing with friends, outside home, including on evenings 
The results (Table 5) were that there were no associations between these variables and the 
GMFCS levels, with or without adjustment for ID. Being in levels III-V on the MACS was 
negatively associated with the outcomes of variables 3 & 4 when not adjusting for ID. Being 
in levels III-V on the CFCS was negatively associated with the outcomes of all variables 




Table 5. The association between the dichotomized levels of the GMFCS, MACS and CFCS, 
and ID on selected social outcomes. Statistically significant results in bold. 
 Crude odds ratios (95 % CI) 
GMFCS MACS CFCS ID 
Moved out 0.8 (0.2 – 3.4) 0.3 (0.03 – 1.6) 0.3 (0.03 – 1.5) 0.3 (0.1 – 1.5) 
Intimate 
relationships 
0.9 (0.3 – 2.9) 0.5 (0.2 – 1.8) 0.2 (0.1 – 0.7) 0.3 (0.1 – 1.0) 
Employed and/or 
higher education 
0.3 (0.1 – 1.1) 0.1 (0.01 – 0.6) 0 (0 – 0.1) 0 (0 – 0.1) 
Independent 
personal finances 
0.3 (0.1 – 1.2) 0.1 (0.001 – 0.5) 0 (0 – 0.2) 0 (0 – 0.1) 
Socializing with 
friends, including on 
evenings 
0.8 (0.2 – 2.8) 0.3 (0.1 – 1.1) 0.1 (0.03 – 0.5) 0.1 (0.03 – 
0.6) 
 Odds ratios adjusted for ID (95% CI) 
GMFCS MACS CFCS 
Moved out 1.7 (0.4 – 7.9) 0.5 (0.1 – 3.8) 0.4 (0.03 – 5.3) 
Intimate 
relationships 




NA NA NA 
Independent 
personal finances 
NA NA NA 
Socializing with 
friends, including on 
evenings 
4.3 (0.8 – 24.2) 1.2 (0.2 – 5.5) 0.2 (0.02 – 2.0) 
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CFCS: Communication Function Classification System.  
CI: Confidence Interval. GMFCS: Gross Motor Function Classification 
System. MACS: Manual Ability Classification System. NA: Not available. 
ID: Intellectual disability 
It was impossible to delineate the association between the GMFCS and the MACS with 
adjustment for ID on variables 3 & 4 because both ID and the CFCS completely predicted the 
outcome on these variables, meaning that having ID and/or being in CFCS levels III-V meant 
that the young adult always (100%) answered no on these items. 
To summarize, being in high functioning or low functioning gross motor classification levels 
did not make any detectable difference on these social outcomes. The manual ability 
categories had some impact, but the effect of communication function categories was very 
pronounced as was having intellectual disability. 
These results can be approached from two perspectives. The descriptive results are absolute 
proportions. They are more informative if they can be compared to data on individuals 
without CP in order to gauge whether individuals with CP are disadvantaged on these 
outcomes. As this was a cross-sectional study without a dedicated control group this analysis 
was not the primary scientific value of this investigation. To evaluate and discuss the results 
of the association analyses are more important as these give hints on the impact that different 
dimensions of functioning have on social outcomes. Both aspects also need to be compared 
with the results from other studies. 
Starting with the descriptive results, the item on housing can be compared to official Swedish 
statistics. Forty-four percent (Official Swedish Statistics, 2016a) of 21-year old young adults 
in Sweden had moved out from the parental home in the year 2016. This is more than twice 
as many as in the group of young adults with CP. Keeping in mind that the official statistics 
refer to Sweden as a whole, and that the capital of Stockholm tends to have a more difficult 
housing market, this would still indicate that young adults with CP remain in the parental 
home to a larger extent than typically developed peers. In a report from southern Sweden 
(Alriksson-Schmidt et al., 2014), 43% of young adults with CP in the age span 18 – 24 years 
had moved away from home. This figure would seem to be more in line with the general 
population and contradict the results. However, of the very few studies in this field two other 
studies on adults with CP have both demonstrated that housing independent of the parental 
families is more rare if you have CP: in Australia 35% vs 78% for typically developed (age 
span 20 – 30 years), and in Denmark 68% vs 92% (age span 29 – 35 years) (Michelsen et al., 
2006; Reddihough et al., 2013). All in all, this would appear as an area in need of 
improvement as independent living has been highlighted as a particularly important goal by 
young adults with CP (Bjorquist et al., 2015; Nguyen et al., 2016; Tornbom et al., 2013). Our 
results did not show any significant effect of the domains of functioning on housing, but there 
were few individuals who had moved away from the parental home on this item and 
associations were therefore unlikely to appear. It is likely that the solutions that enable young 
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adults to move away from home are in the political and societal domain. On the one hand this 
requires housing that is accessible both physically and financially, on the other hand 
strengthened personal assistance that can replace the need for the parental family to perform 
day-and-night ADL for their young adults (which was the case amongst 43% in this 
material). 
Occupation is another item where comparisons with the general population is possible. 
According to official Swedish statistics (Official Swedish Statistics, 2016b) 9% of the age-
matched general population were neither employed or studying. In our sample 15% overall 
and 21% of young adults without ID had no activity. Similar proportions have been reported 
from studies performed in the Netherlands (Verhoef et al., 2014). This again would appear as 
an area where individuals with CP are disadvantaged and where active policy making is 
needed. There were some clear associations on this item with regards to the dimension of 
functioning. The levels in the MACS and the CFCS were both strongly associated with 
employment and/or higher education, as was ID. In fact, being in levels III-V on the CFCS or 
having ID equated to always answering no on this item in this sample of young adults.  
4.1.2.1 Intellectual disability as a confounder 
The results clearly show that the levels in the CFCS and ID are major determinants of social 
outcomes in young adults with CP. The levels in the MACS also show associations. The 
question arises if these are independent associations or if the results, especially the CFCS 
results, are confounded by ID (as being associated with both lower functioning levels on the 
classification systems as well as associated with the social outcomes).  
Table 6. Correlations between the levels in the classification systems and intellectual 
disability 




Spearman’s correlation coefficient. ID: Intellectual disability 
The correlation coefficients (Table 6) represent the strength with which the levels in the 
classification systems and ID are in this sample. This represents the first argument of why ID 
cannot explain the bulk of the association results. The GMFCS and the MACS display the 
same strength of association with ID, but the GMFCS was not associated with any of the 
social outcomes while the MACS was.  
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The correlation coefficient is high between the levels of the CFCS and ID. In non-technical 
terms: if a young adult was categorized within lower functioning levels in the CFCS, he or 
she was likely to also have ID, and vice versa. However, the CFCS displayed an independent 
result (Table 4) on the item of intimate relationships when the regression was adjusted for 
presence of ID – indicating a separate mechanism of participation restriction. As a more 
cautious and weak indication, it can be noted that the direction and magnitude of the other 
odds ratio estimates remained more or less the same when adjusting for ID, but that the 
estimates became less precise with non-significant confidence intervals. 
4.1.2.2 The results in relation to the literature 
The question is if other studies have seen the same results of the impact of ID and lower 
communication functioning – the answer is more or less affirmative. Comparisons are 
somewhat hampered by the use of different definitions and by different inclusion criteria. In 
their study on 20-30 year old adults with CP in Australia, Reddihough and colleagues found 
that “average intellect” was a predictor of independent living and living with a partner, and 
that “average intellect” and “lack of any speech impairment” both were independent 
predictors of secondary school completion(Reddihough et al., 2013). In the US, Murphy and 
colleagues noted that cognition affected employment status, but not physical impairment and 
interestingly also not “communicative impairment” (Murphy et al., 2000). In the Netherlands, 
Tan et al have found that epilepsy, “speech impairment” and intellectual disability had a 
negative influence on social participation (Tan et al., 2016; Tan et al., 2020).  
It is also worth noting what dimension of functioning that did not have an impact on the 
social outcomes: the gross motor function classification. It did not seem to matter whether 
you were a habitual walker with or without aids or mainly used wheeled mobility when it 
comes to the studied social outcomes. In the study from southern Sweden (Alriksson-Schmidt 
et al., 2014), GMFCS and MACS levels correlated with living arrangements when these were 
separated into “independent living”, “living with parents” and “special service housing”. If 
you revisit the data and analyze the association between “living with parents” and the 
GMFCS-levels, there is however no association (p=0.391) (data not shown). This is in line 
with the findings in paper I. The question is also if the moderate associations found 
(Alriksson-Schmidt et al., 2014) between the GMFCS and MACS with regards to 
occupational status would remain significant if these were adjusted for ID. In the Danish 
study (Michelsen et al., 2006), an analysis of living arrangements in a large adult population 
with CP with adjustment for, amongst other things, IQ-levels, found that gross motor function 
only influenced the results marginally. Similar conclusions were made in the Australian study 
(Reddihough et al., 2013). 
It would appear, if the goal is to maximize social integration in adults with CP, that emphasis 




4.1.3 Health-related quality of life, pain, and fatigue 
In summary, the results in paper II were as follows 
• Overall HRQoL (or health status) of young adults with CP was similar to that of the norm 
population 
o Mental health status was reported as higher by young adults in GMFCS levels III-
V as compared to levels I-II 
o Physical health status was reported as lower by young adults in GMFCS levels 
III-V as compared to levels I-II and as compared to the norm 
o Lower physical health status was associated with a sedentary lifestyle – but this 
finding can be explained by the fact that both were associated with being 
classified within GMFCS levels III-V 
• Pain was reported by 33 % in the preceding 24 hours and by 49% in the preceding four 
weeks. 
o Pain prevalence showed little variance across GMFCS levels 
o Pain locations were similar to previous descriptions of individuals with CP 
o There were (surprisingly) few predictors of pain; female sex was independently 
associated with having more pain 
• Being fatigued was reported by 41% 
o Prevalence of fatigue was fairly even across GMFCS levels I-IV with a higher 
(67%) prevalence in GMFCS level V 
o Mean fatigue severity decreased with increasing level of physical activity 
It was also shown that 
• Twenty-eight percent reported being physically inactive, while the remaining 72% 
reported engaging in various intensities of regular physical activity. 
• Sleep problems were reported by 41% of participants, with a 70% prevalence in 
GMFCS level V 
• Sixteen percent were using antidepressant pharmacotherapy 
• Only 40% of young adults categorized as being in GMFCS level I were enrolled in 
specialized rehabilitation services 
4.1.3.1 Health-related quality of life 
The overall HRQoL (or health status) results are welcome findings. The results can help 
reassure patients and families with a general positive outlook on HRQoL. These findings 
align with the results of other recent studies. From the CPUP Adult registry in Sweden, Jarl 
and colleagues described EQ-5D results of primarily high motor functioning adults with CP 
and found a generally high HRQoL (Jarl et al., 2019). Results on QoL of adolescents with CP 
reported from pooled European data (Boldyreva et al., 2020) were equal to the general 
population. They also found that proxies (parents) rated QoL of the adolescents as lower 
compared to self-reporting, a phenomenon which has been previously described (Andresen et 
al., 2001; White-Koning et al., 2007) and which is of interest in the analysis of the sub-group 
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results in the current data set. Jiang and colleagues in Australia also found that proxies for 
young adults with CP reported significantly lower QoL than those whom were able to self-
report. Interestingly, they also found that psychological well-being was good in young adults 
in lower-functioning gross motor levels. (Jiang et al., 2016) 
The most striking difference in HRQoL across GMFCS levels was when the results were 
divided into the main component scores of the SF-36v2; the PCS and the MCS. Not 
unexpectedly, physical health status (PCS) was reported as poorer by individuals with more 
extensive motor limitations. However, limitations in movement is likely not the only cause; 
as described in the Introduction (section 1.1.2) individuals within lower motor functioning 
levels in the GMFCS are more likely to also have accompanying co-morbidities such as 
epilepsy and hearing and vision impairments. The results on mental health status (MCS) are 
somewhat more unexpected. Young adults in GMFCS levels III-V reported better mental 
health status than young adults in GMFCS levels I-II. The differences were not as 
pronounced as for PCS (where the association was the other way around), but still apparent. 
So, are these findings valid? First, young adults in GMFCS levels III-V are more often 
assisted by a proxy or represented by a proxy when reporting their HRQoL. The correlation is 
high between GMFCS levels and the use of proxies (Spearman’s correlation coefficient 0.72, 
p < 0.001). If proxy-responders overestimate HRQoL it could explain the better mental health 
status. This could however only explain the present results if proxies differentially 
overestimate mental health status while not overestimating physical health status. This 
appears unlikely. Secondly, as described previously, other researchers have shown that 
proxies tend to underestimate HRQoL (Andresen et al., 2001; Boldyreva et al., 2020; White-
Koning et al., 2007). If this apparently inherent bias of proxy-reporting is applied to the 
present results it would mean that physical health status is actually less poor and mental 
health status even better in young adults classified within levels III-V on the GMFCS. We 
can therefore assume that the better mental health status in young adults in GMFCS levels III-
V is valid. This is a welcome finding in the sense that this can help reassure families with 
children classified within these levels.  
It could be speculated that the result is due to frames of reference – what you as an individual 
compare yourself to. This is also what was generally perceived during the visits for the data 
collection. In this theory, youth with minor activity limitations have typically developed peers 
as their frame of reference, while youth with major activity limitations have other youth with 
major activity limitations as their frame of reference. High motor-functioning individuals are 
in the first instance at risk of underestimating their own abilities and capacities because the 
ruler by which they gauge their own performance is constantly that of peers without physical 
disability. This theory can however not fully explain the results. Although there was a 
substantial variance in MCS results (considerably more than for PCS) the group differences 
were primarily driven by the fact that young adults in GMFCS levels IV-V tended to score 
higher MCS results than the norm, and not that young adults in GMFCS levels I-II scored 




The results on pain in young adults with CP are for the most part congruent with what has 
now been reported within the field. The pain prevalence (33 – 49%) falls within the rather 
broad interval (14 – 76%) identified in the most recent systematic review (McKinnon et al., 
2019) of studies on pain in children and young adults with CP. That female sex is a risk factor 
for pain is also in line with the literature (Jahnsen, Villien, Aamodt, et al., 2004; McKinnon et 
al., 2019). The results did not show any association between having severe spasticity (MAS ≥ 
2 in any examined muscle group) and having pain and the results do not therefore support a 
general group-level relation between these two. 
The present results come with norm comparisons. Percentages and prevalence aside, the 
result is that the combined pain intensity and pain interference (as assessed on the SF-36v2) 
was very similar to age and gender matched norm comparisons. This result is also a welcome 
finding. Would this then mean that pain is not more of an issue in CP than in the general 
population? The answer to that question is no, but it requires some explanation. First, pain in 
CP appears to be, in many cases, progressive with age (Alriksson-Schmidt & Hagglund, 
2016; McKinnon et al., 2019), becoming a more pronounced problem for older adults with 
CP (Jahnsen, Villien, Aamodt, et al., 2004; Opheim et al., 2009). Secondly, the characteristics 
of pain in CP in youth with CP differ from comparison population. While adolescents in the 
general population typically report headaches as the most common complaint, adolescents 
with CP typically report lower extremity pain (McKinnon et al., 2019), and in paper II back 
pain. The approach and management are therefore different, and pain in CP requires special 
considerations. Being in GMFCS level V has been found to be a particular risk factor for 
having pain (McKinnon et al., 2019) (with pronounced musculoskeletal deformities as the 
mechanism) but this could not be confirmed in the present study, where pain severity was 
similar across GMFCS levels. Proxy-reports of pain have been found to underestimate the 
extent of pain (White-Koning et al., 2007). This bias could mean that the true pain severity 
was higher in GMFCS level V. However, all other studies on this population should suffer 
from the same bias and thus it is not apparent where this discrepancy stems from. Of interest 
is that the results highlight that young adults in higher functioning GMFCS levels are not pain 
free – it would appear to be just as much a problem in this group as in lower functioning 
GMFCS levels. This is of importance as it was uncommon for young adults in GMFCS level 
I to be connected to specialized services – leading to a higher risk that these issues go 
unmanaged and may have bigger consequences later on in life. 
4.1.3.3 Fatigue, and physical activity 
The cut-off for when you are considered to be fatigued has in different populations, including 
CP, been set at an FSS mean score of 4.0 or above (Russchen et al., 2014; Valko et al., 2008). 
Using this cut-off, a considerable proportion of the sample of young adults were fatigued. 
Fatigue has increasingly been recognized as an important co-morbidity of CP with important 
consequences for health and well-being (Benner, Hilberink, Veenis, Stam, et al., 2017; 
Brunton & Bartlett, 2017; Sienko, 2018; van der Slot et al., 2012; van Gorp et al.). 
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Interestingly, an association between higher and higher levels of physical activity and less 
and less fatigue was observed here, a finding reported also by McPhee and colleagues 
(McPhee et al., 2017) whom assessed physical activity using accelerometers. While both 
studies are cross-sectional and unable to give a causal explanation (it could be that being 
fatigued prevents being physically active as well as the other way around) the results open up 
for interventional studies – interventions based on further promoting physical activity. Pilot 
studies have shown positive results (Slaman et al., 2015; Vogtle et al., 2014) and should be 
followed on by confirmatory studies. 
Young adults in the present sample were generally more physically active than was reported 
from southern Sweden (Waltersson & Rodby-Bousquet, 2017). Interestingly and somewhat 
disappointing was that physical activity showed no association with pain prevalence or 
severity, neither in the present sample nor in the study from southern Sweden (Waltersson & 
Rodby-Bousquet, 2017). 
4.1.3.4 Sleep 
A large proportion of the young adults reported sleep problems (41%), defined as difficulties 
in establishing and/or maintaining sleep to such an extent that it negatively impacts on daily 
life. This is similar to the 46% recently reported (Petersen et al., 2020) in school aged 
children in Australia and exactly the same proportion as found in another study from the 
neuropediatric unit at the Karolinska Institutet in children with CP (Löwing et al., 2020) but 
higher than the 23% reported by a systematic review including studies up to 2018 (Horwood 
et al., 2019). Sleep problems were in the present results particularly common in young adults 
in GMFCS level V, where also a majority used sleep medications regularly. This highlights 
that sleep issues should be actively sought and addressed when meeting young adults with CP 




4.2 TREATMENTS FOR SPASTICITY AND PAIN 
4.2.1 Long-term results after selective dorsal rhizotomy 
The SDR procedure, as performed at the Karolinska University Hospital between the years 
1993-1997, appeared to be relatively safe. Adverse events consisted of postoperative 
hypotonia in the lower extremities as well as calf spasms, which were transient complications 
in all children. Sensory complications in the form of hyperesthesia in the lower extremities 
did occur in a majority of the children, resolving over weeks to, in a few cases, several years 
after the procedure. One child had transient urinary incontinence in the immediate 
postoperative period.  
With regards to the efficacy of the procedure, it was found that 
• Spasticity was markedly reduced or normalized, with only a slight recurrence of 
spasticity in the knee flexors and plantar flexors in some children at the 10-year 
follow-up 
• Gross motor function improved significantly between baseline and 18 months,  and 
between 18 months and 3 years; it subsequently declined between 3 years and 10 
years – still with a significant improvement compared to baseline status 
• Mobility function was improved in 12 children, was unchanged in two, and worsened 
in five children at the 10-year follow-up compared to baseline 
• After an initial increase in joint range of motion at the hip, knee and ankle level up to 
the 3 year follow-up ROM decreased, and all but three children underwent orthopedic 
surgeries (with tendon lengthening procedures being most common) 
It can be safely concluded that the SDR-procedure produced a marked and near permanent 
reduction or normalization of muscle tone – very few children required additional tone 
management in the form of BoNT-A and none had received such treatment in conjunction 
with the follow-ups. It can also be safely concluded that the procedure, and the subsequent 
reduction of spasticity that it produced, did not prevent contracture development. It is not 
proven that it did not slow down contracture development (there was no direct comparison 
group), but it certainly did not prevent it.  
But what about functional gains? In order to correctly interpret the results of the GMFM-88 it 
is important to understand the natural progression of gross motor function with age in 
children with CP. Figure 3 represents data (Hanna et al., 2009) on the predicted development 
of gross motor function (GMFM-66) as a function of age, by GMFCS levels. The study 
describes that, on group level, children in GMFCS level I reach a mean GMFM-66 
(minimum 0 – maximum 100) score of 85-90 in the age span of 9-12 years of age. Children 
in GMFCS level II reach a mean GMFM-66 score of about 70 by the same age span of 9-12 
years of age. Both groups then maintain a stable gross motor function into adolescence and 
young adulthood. Children in GMFCS levels III-V differ from this pattern in that they reach 
their maximum gross motor function somewhat earlier, followed by a decline in gross motor 
function into adolescence and young adulthood. This decline is most pronounced in GMFCS 
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level IV (Hanna et al., 2009).  The existence of these distinct gross motor function trajectories 
has been confirmed in a separate population (Smits et al., 2013). However, in that study 
(Smits et al., 2013) no decline of function in GMFCS levels III-V was seen. The populations 
were however not entirely compatible. Young adults with ID were excluded, which the 
authors believe significantly skewed the subgroups in GMFCS III-V towards better motor 
prognosis (Smits et al., 2013).  
 
Figure 3. Gross motor function scores as a function of age by Gross Motor Function Classification (GMFCS) 
level. Dashed lines indicate peak gross motor function scores for levels III – V. From Hanna et al. 2009. 
Reprinted with permission. 
Given that the mean age was 4 years and 7 months at surgery it is expected that the mean 
GMFM should increase substantially from the baseline examination to the 3-year follow-up. 
It is, likewise, given the large proportion of children in GMFCS level IV, expected that the 
GMFM should decrease at the 10-year follow-up. The results can therefore be said to mimic 
the typical expected development of gross motor function in these children. It cannot be 
safely concluded that the procedure resulted in better than expected gross motor function, nor 
that it worsened it. 
It is unfortunately not possible to do more precise comparisons due to a couple of reasons. 
First, the development curves (Figure 3) appear appealing for direct comparisons (e. g. by 
plotting the GMFM-88 data from paper III onto the curves) but behind the curves is a 
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substantial variance in individual gross motor function within the different GMFCS levels 
(Hanna et al., 2009). The present sample would have to had been considerably larger for such 
statistical comparisons to be meaningful. Secondly, children whom are offered SDR do not 
represent average children with CP. As can be noted in the inclusion criteria children whom 
are offered SDR must have good cognition, good trunk control, adequate muscle strength, no 
dystonia, and be able to adhere to intensive pre- and post-operative training programs. The 
last variable is complex and probably involves high-functioning aspects of cognition, 
attention, and executive performance as well as a supportive and capable environment. These 
children are therefore a subgroup where all share positive predictors of particularly good 
motor development. Carefully selected control groups are needed for comparisons to be 
accurate – with so many factors to account for it is probably only achieved through 
prospective randomization to the procedure or to control. 
Other studies have since found similar spasticity-reducing efficacy in long (≥ 10 years) 
follow-ups (Ailon et al., 2015; Josenby et al., 2012; Munger et al., 2017). It can be generally 
concluded that SDR reduces spasticity even though most studies do not have a control group. 
The natural progression of spasticity in the gastrosoleus muscles with age in children with CP 
has been reported from the Swedish CPUP program (Linden et al., 2019). In summary, 
spasticity increases in severity up to a peak at about 5-6 years of age, followed by a gradual 
reduction (not, however, to normal muscle tone on the group level). Although spasticity in the 
gastrosoleus muscles peak around the same time as many children undergo SDR (Linden et 
al., 2019), and the decline in spasticity therefore could be thought of as natural development 
with age, the magnitude of the rapid and sustained reduction/normalization of spasticity in 
children whom have had SDR performed is probably not explained by this natural 
progression alone.  
So how about function? This is a subject of considerable debate (Park, 2020; Tedroff et al., 
2020). Many long-term case series have expressed positive conclusions about the effect of 
SDR on gross motor function and activity (Bolster et al., 2013; Dudley et al., 2013; Hurvitz et 
al., 2013; Josenby et al., 2012; Langerak et al., 2009; Park et al., 2017; Romei et al., 2018). 
There are however methodological limitations to these case series with medium to high risks 
of biased results (Tedroff et al., 2020). Attrition of participants in the case series (making 
some significantly non-consecutive) is one major methodological limitation in many follow-
ups. Notwithstanding these limitations, the trend is clear that most (but not all) children in the 
follow-ups have better gross motor function, in absolute percentages, at the long-term follow-
up compared to pre-operative status. In this sense the present study data is not much different 
from that of other follow-ups at other centers. The main difference is in the interpretation of 
the data. The natural development of gross motor function and the selection process for SDR 
are major confounders, which need to be addressed before any assertion is made that SDR 
has resulted in long-term improvement. First, as expanded on previously it is expected that 
gross motor function should improve with age in childhood (followed by a probable decline 
in certain groups). Secondly, even those follow-ups that report better-than-expected gross 
motor function development (Bolster et al., 2013; Josenby et al., 2012) fail to acknowledge 
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the impact of the selection process for SDR. As mentioned before these children represent a 
subgroup of children with CP with particularly good positive predictors of motor 
development and particularly little occurrence of negative predictors. It could therefore be 
argued that children whom are candidates for SDR have a particularly good gross motor 
prognosis regardless of the intervention. Again, adequate control groups are crucial if you 
wish to conclude that SDR delivers superior results on gross motor function. Two case-
control studies of long-term functioning have been published (Daunter et al., 2017; Munger et 
al., 2017). Daunter and colleagues concluded that SDR leads to superior long-term 
functioning compared to those whom have not been operated on (Daunter et al., 2017). 
However, the control group was not representative of the SDR-group. For example, the 
control group included individuals with subtypes of CP, and presence of impairments, that 
are exclusion criteria for SDR. Munger and colleagues went further methodologically to 
assign a representative control group, which was also confirmed using propensity matching 
modelling (Munger et al., 2017). They found that study outcomes were similar for both the 
SDR group and the non-SDR group, with gait quality actually better in the control group. 
Neither study have however shown that they have controlled and matched for cognition, 
selective motor control, presence of dystonia, and perhaps most importantly, the ability to 
participate in intensive training programs. So, addition of control groups in long-term follow-
ups is a major step forward on the way to answering the role of SDR in long-term 
functioning. But until studies have been published where the control group has been matched 
also on these important parameters the author of this thesis would argue that the question on 
the effect on long-term functioning remains unanswered.  
That contractures develop despite SDR has been seen in other follow-ups (Ailon et al., 2015; 
Munger et al., 2017) and has become more or less accepted as established knowledge, 
together with increased knowledge of the underlying mechanisms behind the progressive 
shortening of muscles in CP and the limited role of spasticity in this development (see section 
1.3.1 of the Introduction). There is however debate as to whether SDR could decrease (not 
prevent) the extent of contractures. At least two studies (Josenby et al., 2012; Munger et al., 
2017) argue that contractures appear less extensive in those whom have undergone SDR 
based mostly on frequency and type of add-on orthopedic interventions. Again, until 
comparisons have been made with fully representative control groups, the question of a 
partial effect of SDR on the extent of contracture development remains unanswered. 
There are other possible beneficial effects of SDR. One is that a near-permanent reduction of 
spasticity could, in some cases, perhaps prevent later development of some types of pain. 
Low pain intensity and low pain interference were found in an even later follow-up of this 
particular cohort (Tedroff et al., 2015). The study by Munger and colleagues found similar 
results; that pain interference was markedly low in the SDR group long-term, however, the 
control group also reported low pain interference and there was no statistically significant 
difference between groups (Munger et al., 2017). The issue requires further exploration. 
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4.2.2 Botulinum toxin-A for muscle-related pain 
The main results of paper IV are as follows. 
Primary outcome: 
• There was no difference in the proportion of responders on pain intensity (defined as 
a reduction of pain intensity ≥ 2 NRS compared to baseline, at six weeks after 
treatment) in the BoNT-A group (4 responders, 4 non-responders) and the placebo 
group (4 responders, 4 non-responders). 
Secondary outcomes: 
• There was no statistically significant difference in analgesics use between the BoNT-
A group (5 decreased, 2 unchanged, 1 increased) and the placebo group (2 decreased, 
4 unchanged, 2 increased). 
• There was no difference in the proportion of responders on pain interference (defined 
as a reduction of mean pain interference of ≥ 1 on the BPI compared to baseline, at 
six weeks after treatment) in the BoNT-A group (4 responders) and the placebo group 
(4 responders). 
Exploratory outcomes: 
• The mean and median pain intensity continued to trend downwards in the BoNT-A 
group, while returning to baseline in the placebo group. At ten weeks after treatment 
(the last follow-up), the mean and median pain reduction was -2.0 NRS in the BoNT-
A group and 0.0 NRS in the placebo group.  
• Muscle spasticity was reduced in 80% of treated muscles in the BoNT-A group and 
50% of treated muscles in the placebo group. There was an equal proportion (around 
40% in both groups) of improvements in ROM. 
• There were no significant differences in the change of fatigue severity, HRQoL or 
Patient’s Global Impression of Change Scale in between groups. The SF-36v2 
subdomain that showed the largest difference was that of an improvement in Bodily 
Pain in the BoNT-A group (+8.2, p=0.055). 
The study was stopped at the interim analysis (see Methods, section 3.3.3.1) due to futility of 
the primary outcome when 16 participants had finished the study. At this point, there was an 
equal proportion of responders in the BoNT-A group as in the placebo group and the 
probability of achieving success on the primary outcome was assessed to be less than twenty 
percent. 
The details of the recruitment process are described in paper IV, especially Figure 1. Fifty 
individuals were screened for eligibility: the most common reason for not being included in 
the study was that the individual presented with pain that could not be attributed to spasticity. 
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4.2.2.1 Interpretation of the results – the recruitment process 
The recruitment process shows that only a fraction of adults with spastic CP with chronic 
pain referred for study screening did indeed have pain that could be attributed to spastic 
muscle. Other pain mechanisms that were commonly seen included arthralgia, idiopathic 
lower back pain and neuropathic pain. This finding highlights the need to further study the 
specific clinical characteristics of chronic pain in adults with CP – spasticity is but one of 
many possible mechanisms. 
4.2.2.2 The results on pain intensity 
The trial can conclude, with reasonable powerd, that BoNT-A was not superior to placebo at 
six weeks after treatment. 
Given the results, it would however appear that our initial assumption that pain reduction 
following BoNT-A would be most pronounced around six weeks after treatment was 
incorrect. Will and colleagues had the same preconception in their RCT on preoperative 
BoNT-A vs placebo in bony hip surgery with the primary outcome at six weeks after 
treatment (Will et al., 2019). The results suggest that pain reduction after BoNT-A comes 
later, at least for muscle-related pain, whereas the effect of placebo injections wane off 
quicker. This has implications for future studies on this subject. 
4.2.2.3 Assessment of the justification for further trials on this treatment 
Results supporting that further trials are warranted 
• The trend of a continuous reduction of pain intensity at the last follow up in the 
BoNT-A group. 
• The trend that more participants reduced their concomitant use of analgesics in the 
BoNT-A group. 
• The trend that Bodily Pain in the SF-36v2 measurement was reduced in the BoNT-A 
group. 
• The appearance of individual sustained pain reduction responses in the BoNT-A 
group compared to mixed transient results in the placebo group (Figure 3b in paper 
IV). 
Results that speak against further trials 
• There were no appreciable group differences on pain interference (i. e. how much 
pain interferes with ADL), which has been argued to be an endpoint at least as 
important as pain intensity(Dworkin et al., 2005). 
• There were no appreciable group differences on HRQoL. 
 
d The study had an original power (1-ß) of 0.8 (80%), which after the interim analysis (<20% probability of a 
positive primary endpoint) produces a post hoc power of 0.8 x 0.8 = 0.64 or better (>64%). 
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• The size of the final study, in terms of number of study participants, was small, which 
increases the risk of chance findings. 
Taken together with the fact that there is a fairly widespread off-label use of BoNT-A on this 
indication, which needs to become evidence-based, the overall conclusion is that it appears to 
be justification for further trials of longer duration. 
4.3 METHODOLOGICAL CONSIDERATIONS AND RISK OF BIAS 
4.3.1 General comment on patient reported outcomes 
The last few years have seen the development and implementation of PROMIS (Patient-
Reported Outcomes Measurement Information System), which is an initiative by the US 
National Institute of Health (NIH). The goal was to develop a "psychometrically validated, 
dynamic system to measure patient reported outcomes efficiently in study participants with a 
wide range of chronic diseases and demographic characteristics"(HealthMeasures, 2020). 
PROMIS measures cover physical, mental, and social health. These measurements have now 
found use in research in cerebral palsy and should be considered for future studies with aims 
similar to the ones presented in this thesis. 
4.3.2 Papers I & II 
A mailed survey would have been a more typical approach to data collection in papers I and 
II. Benefits with a mailed survey would possibly, but not definitely, include a higher 
inclusion rate because of the relative ease of answering the questions at home instead of 
together with the examiner. The benefits of having a data collection through direct contact 
with one or a few investigators include that items that the participant feel are unclear can be 
clarified (increasing accuracy), that the same approach to the items is used consistently 
(increasing accuracy and decreasing differential misclassifications) and that incongruent 
responses from the participant can be addressed (again, increasing accuracy). 
While the recruitment approach targeted an age-specific total population, the final sample 
was a lesser proportion: 32% of the entire target population or 44% of those where contact 
could be made. Distribution of sex, GMFCS-levels, and prevalence of epilepsy and ID all 
matched expected proportions, which gives strong evidence of a representative sample. There 
is however still the possibility that those who agreed to participate differ in some respects 
compared to those who did not. The main concern is that of selection bias(Hernan et al., 
2004), i. e. that the possibility of being included in the study is associated with the outcome. 
To put it in an example: that those who participate tend to have higher or lower HRQoL, or 
better or worse social outcomes, than those who did not participate. This is a particularly high 
risk in convenience samples. The fact that the present sample of young adults, which was not 
a convenience sample, had expected frequencies on the most central variables and 
comorbidities down-plays this risk but does not eliminate it. There are examples where it has 
been shown that more pronounced disease severity is coupled with an increased willingness 
to participate in cross-sectional studies (Apfelbacher et al., 2009). If this bias is present in this 
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data collection it would mean that the direction of the bias is that of overestimation of 
‘disease severity’, in this study translated into that health status, pain, fatigue and social 
outcomes are in fact better in young adults with CP than what the present results show.  
The use of proxy-responders enabled the study to include young adults with CP within all 
levels of functioning. This was a strength of the study. However, the use of proxies 
introduces risks of bias. As discussed in section 4.1.3.1, proxies tend to underestimate 
HRQoL. This could mean that HRQoL could be even higher than reported in those who were 
assisted by proxies. And as discussed in section 4.1.3.2, proxies tend to underestimate pain. 
This could mean that pain actually is more of an issue in those who were assisted by proxies. 
The instruments used to assess HRQoL, pain, fatigue, physical activity etc. were not disease-
specific and not specifically tailored to individuals with childhood-onset disability. This 
introduces some likely degree of measurement error. This measurement error was likely non-
systematic (apart from that stated about proxy responses above) and therefore probably 
resulted in some decreased accuracy. Habitual physical activity is difficult to evaluate in 
individuals in GMFCS levels IV-V and is overall probably better evaluated using wearable 
accelerometers (Clanchy et al., 2011) and perhaps wearable heart rate monitors. 
The studies lacked data on bullying and ostracism. These are common burdens in individuals 
with disabilities (Holmberg, 2010; Twyman et al., 2010), including CP (Lindsay & 
McPherson, 2012), which have negative effects on health status (Holmberg, 2010; Whitney et 
al., 2019). There is not much research done on bullying and social exclusion in CP and the 
effects they have on health and well-being. It is unfortunate that this was not included in the 
data collection as it has the potential to add additional clarity to the results and associations 
that were found. Future studies should incorporate these aspects. 
4.3.2.1 External validity 
The overall results should be generalizable to young adults about 21 years of age with CP 
living in societies with similar health-care systems and social support structures as in 
Sweden. Some findings, which are less environment-dependent, such as the association 
between less fatigue and more physical activity can probably be generalized even more 
broadly. 
4.3.3 Paper III 
The internal validity of the study should be considered adequate. The core outcome measure 
of gross motor function (GMFM-88) has largely been superseded by the GMFM-66 but it is 
still a valid and reliable gross motor measure. The use of the MAS to measure spasticity has 
its shortcomings (see Introduction section 1.3.1 and Methods section 3.5.7) but it remains the 
most widespread method, including most studies on SDR. A risk that has been reported is 
that the MAS has the potential to systematically misclassify contracture as spasticity when 
contractures are present (Patrick & Ada, 2006). Given that the MAS measurements were high 
preoperatively (before the development of contractures) and low at the long-term follow-up 
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(after contractures developed) means that any such misclassification, if present, had a 
minimal influence on study conclusions. For mobility, the Wilson Gait (Mobility) Scale has 
found little use in CP, where mobility more often is measured using the Function Mobility 
Scale (Graham et al., 2004). The FMS includes more options on wheeled mobility devices. It 
is possible that the results on mobility would have been different if the FMS was used.  
The operations were performed with largely the same techniques as reported by other centers 
regarding intraoperative neurophysiology and percentage of rootlets cut.  
Unfortunately, the follow-up did not include systematic radiography of the spine. Spinal 
complications are thus not systematically captured. 
The Karolinska cohort of children whom had SDR had a similar distribution of GMFCS 
levels as the Lund cohort (Josenby et al., 2012) and the Vancouver cohort (Ailon et al., 2015) 
but more participants in GMFCS level IV compared to the Gillette cohort (Munger et al., 
2017) and the Dutch cohort (Bolster et al., 2013), which has implications for the 
interpretation of the development of gross motor function at the group level. 
4.3.3.1 External validity 
The inclusion and exclusion criteria are in line with those previously and currently practiced 
for SDR and the general results should be generalizable to children undergoing SDR at most 
centers where strict selection criteria are implemented. The SDR method produces a 
significant and lasting reduction of spasticity without direct manipulation of the joint or 
muscle and therefore serves as a good experimental model for the study of spasticity 
reduction on contracture development. That contractures develop despite reduction or 
removal of spasticity, as measured using the MAS, can be generalized. 
4.3.4 Paper IV 
The paper can be argued to have good to excellent internal validity, mainly due to adherence 
to international consensus on methodology for randomized, placebo-controlled, double-
blinded clinical trials. The blinding process was however not through delivery of coded vials 
from an external study pharmacy, which would be considered gold standard. At the time, in 
Stockholm, this turned out to be financially completely unfeasible. The process of blinding 
where the study nurse prepared coded syringes did however work well in that the blinding of 
the allocation remained intact with regards to both the treating team, the patient and the 
evaluating team.  
From the perspective of the PRO’s, future studies should consider using PROMIS 
measurements for added comparability with other studies, as well as longer registrations of 
baseline pain intensity and interference and perhaps pain follow-ups at shorter intervals using 
smartphone applications. 
The main limitation of the study is however the small number of study participants; the 
sample size. This increases the risk of chance findings. It is however not definite that forty-
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two participants would have made any major difference on the study conclusions compared 
to the present sixteen. This is because the primary outcome (proportion of responders at six 
weeks) was very likely to fail (probability of failure >80%) even if recruitment continued. 
The interesting results and trends presented in paper IV are exploratory, i. e. found by chance, 
and not pre-specified. And these results would remain exploratory even with a larger sample. 
The exploratory results would have less uncertainty, but they would still be exploratory. The 
conclusion from such a study (conducted with the same protocol but a larger sample) would 
be that there seems to be cause for trials of longer duration with the primary outcome later 
than six weeks after treatment. The author of this thesis would argue that we already have 
reached these very same conclusions, and this without exposing unnecessarily many human 
beings to experimental treatment. 
4.3.4.1 External validity 
As with most RCT’s, the generalizability of the results is restricted to those who conform to 
the strict inclusion and exclusion criteria (which are strict in order to maintain internal 
validity in the study). The results are generalizable to adults with spastic CP where the 
dominant pain mechanism is that of spasticity in the muscle: cramping, pulling, tenseness or 







Eighty percent of young adults with CP were still living in the parental home; fewer had 
moved out compared to the general population. Many were still dependent on their parental 
family financially (31%), and for support with ADL on a day-and-night basis (43%). A 
majority (79%) of young adults without intellectual disability were in an occupation. There 
was however an overall increased risk of having no occupation at all. Communication 
function classification level, and presence of intellectual disability, were major determinants 
of the social outcomes. Interventions aimed at alleviating the effect of these particular 
disabilities should be prioritized. 
Overall health-related quality of life, or health status, of young adults with CP was 
comparable to population norms. There were however significant subgroup differences. 
Physical health status was reported as worse in young adults in GMFCS levels III-V, both 
compared to norms and compared to young adults in GMFCS levels I-II. Mental health status 
was however better in young adults in GMFCS levels III-V compared to those in levels I-II. 
Pain prevalence (33-49%) was in line with that of other studies. Female sex, but not spasticity 
nor GMFCS level, was a risk factor for having more pain. Fatigue and sleep problems were 
prevalent, particularly in GMFCS level V. Physical activity could have a protective effect on 
fatigue severity. 
Selective dorsal rhizotomy was a relatively safe procedure at this center. It resulted in a 
markedly reduced or normalized muscle tone. However, contractures continued to form 
during the long-term follow-up and there were no clear positive effects on functioning. The 
results rule out spasticity as the main culprit behind contracture development in CP. 
Botulinum toxin-A was not superior to placebo in reducing chronic muscle-related pain in 
adults with spastic CP when assessed six weeks after a single treatment cycle. There was 
however a trend for a continuing reduction of pain at the last follow-up for the botulinum 
toxin-A group not seen in the placebo group. There is motivation for trials of longer duration 





6 FUTURE DIRECTIONS 
So, is communication function the major determining factor in activity limitations and 
participation restriction in CP? First of all, the results need to be confirmed in other 
populations of young adults with CP, preferably also in larger samples in order to get more 
precise estimates. But what if these exploratory findings were to be confirmed? The question 
then is if it is purely the sending and receiving of information that is the deciding factor, or if 
it is some other variable that is correlated to communication function. Perhaps it is cognition 
after all? It would be intriguing to try to discern, with the help of extensive 
neuropsychological and communicative test batteries, the main cognitive and/or 
communicative factor associated with participation restriction in CP.  
However, this would be looking at the problem from an impairment approach (with the hope 
of finding something that could be ‘fixed’), which is an approach that historically has met 
limited success. The proposed studies should nonetheless be performed, and the results 
integrated with those from studies focusing on identifying environmental barriers for 
participation. It is probable that such an approach, which integrates health conditions with 
contextual factors, would have the best chances of finding ways to improve participation in 
young adults with CP. 
The encouraging overall findings on self-perceived health status (or HRQoL) in young adults 
with CP is, as discussed, in line with recent studies. It would be of value to confirm these 
findings by pooling information from population-based registries that include young adults 
with CP across the globe, using standardized measurements, perhaps PROMIS-
measurements, and applying hypothesis-testing methodology (possibly so-called non-
inferiority design). 
It would also be of value to perform a rigorous randomized controlled trial on physical 
activity interventions with fatigue as a primary outcome. The proposed RCT should probably 
be multi-center given the challenges in reaching an adequate inclusion rate in single-center 
set-ups.  
The long-term effects, including adverse outcomes, of selective dorsal rhizotomy need to be 
further investigated in order to properly determine whether the procedure is beneficial or not. 
Assigning a representative control group is perhaps the most challenging methodological 
aspect (see section 4.2.1). Randomization is essentially what is necessary given the myriad of 
confounders associated with the selection process for SDR. However, maintaining such long-
term randomization is not feasible in the real clinical world. The alternative is therefore to 
conduct case-control studies where the control group has been meticulously matched so that 
only the exposure (in this case, SDR) is what sets the two groups apart. 
Finally, there is an obvious need for evidence-based treatments for chronic pain in CP. There 
is justification for a follow-on RCT on BoNT-A for muscle-related pain in spastic CP. The 
primary endpoint of pain reduction should be set at ≥10 weeks after the treatment; multiple 
treatment cycles could also be considered. The proposed trial should be multi-center to ensure 
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an adequate inclusion rate. In addition, there is a need to learn more about the different types 
of chronic pain presenting in individuals with CP. Spasticity-related pain is but one of many 
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8 SAMMANFATTNING PÅ SVENSKA 
Cerebral pares (CP) är en diagnos innefattande varaktig funktionsnedsättning orsakad av en 
icke fortskridande skada eller malformation som har inträffat tidigt i utvecklingen av barnets 
hjärna. Diagnosen kännetecknas av nedsatt rörelseförmåga och hållning med varierande grad 
av samtidig nedsatt funktion inom kognition, perception, sensorik, kommunikation, samt av 
epilepsi och smärta. Rörelsestörningarna är ofta den mest framträdande komponenten och 
behandlingar har oftast riktats mot just dessa. Behandlingar för att försöka minska spasticitet, 
en typ av abnorm muskelspänning som är vanlig vid CP, förekommer ofta. Då CP är ett 
livslångt tillstånd är det viktigt att förstå de långsiktiga effekterna av behandlingarna, särskilt 
om de genomförs tidigt i livet. Det är också viktigt att förstå hur CP utvecklas över tid och 
förstå vilka delar av funktionsnedsättningen som spelar störst roll när individen växer upp och 
går in i vuxenlivet. Vår kunskap om CP efter barndomen har varit begränsad. Det har 
uppkommit oro kring att individer med CP inte integreras i samhället så väl som man kunnat 
hoppas, samt att nya former av samsjuklighet uppkommer i vuxenlivet, särskilt kronisk 
smärta. Att förstå denna samsjuklighet och att hitta bra behandlingar är ett prioriterat område. 
Denna avhandling fokuserar på hälsa och social situation hos individer med CP i ung vuxen 
ålder, och på behandlingar för spasticitet och smärta. Detta gjordes med hjälp av några olika 
metoder. Hälsa och social situation undersöktes med en tvärsnittsstudie av 20 – 22 åringar 
med CP inom Stockholmsregionen. Långtidseffekterna av den spasticitetsreducerande 
operationen selektiv dorsal rhizotomi (SDR) undersöktes i form av en konsekutiv fallserie. 
Och botulinumtoxin-A (BoNT-A) testades som en behandling för kronisk muskelrelaterad 
smärta hos vuxna med CP i en randomiserad, placebokontrollerad, dubbelblindad klinisk 
studie. 
Resultaten visar att de flesta unga vuxna med CP bodde kvar hemma, fler än i 
jämförelsebefolkningen. Majoriteten av de som inte hade intellektuell funktionsnedsättning 
hade någon form av sysselsättning, men risken för att inte ha någon sysselsättning alls var 
ökad. Den unga vuxnes kommunikativa funktionsnivå, och huruvida det förelåg intellektuell 
funktionsnedsättning, hade avgörande inverkan på den sociala situationen. Den motoriska 
funktionsnivån var av mindre betydelse. Den övergripande hälsorelaterade livskvaliteten var 
på samma nivå som för jämförelsebefolkningen, men det fanns signifikanta gruppskillnader. 
Unga vuxna med uttalad motorisk aktivitetsbegränsning skattade sin fysiska hälsa som låg, 
men tvärtom sin mentala hälsa som god. Unga vuxna med lindrig motorisk 
aktivitetsbegränsning skattade sin fysiska hälsa som god, men sin mentala hälsa som sämre. 
Smärta och fatigue (sjuklig trötthet eller brist på energi) förekom i alla funktionsnivåer. 
Selektiv dorsal rhizotomi hade en varaktigt god effekt på spasticitet, men detta förhindrade 
inte utvecklingen av kontrakturer och inte heller tycktes det ha gett någon avgörande positiv 
effekt på den grovmotoriska funktionen. Botulinumtoxin-A var inte bättre än 
placeboinjektioner på att minska muskelrelaterad smärta hos vuxna med CP vid 
huvudmätningen sex veckor efter behandlingen. Smärtintensiteten fortsatte dock nedåt i 
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